US20230364217A1 - Influenza vaccine, composition, and methods of use - Google Patents
Influenza vaccine, composition, and methods of use Download PDFInfo
- Publication number
- US20230364217A1 US20230364217A1 US18/303,512 US202318303512A US2023364217A1 US 20230364217 A1 US20230364217 A1 US 20230364217A1 US 202318303512 A US202318303512 A US 202318303512A US 2023364217 A1 US2023364217 A1 US 2023364217A1
- Authority
- US
- United States
- Prior art keywords
- influenza
- virus
- mice
- bpze1
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title abstract description 101
- 229960003971 influenza vaccine Drugs 0.000 title description 6
- 206010022000 influenza Diseases 0.000 claims abstract description 63
- 230000028993 immune response Effects 0.000 claims abstract description 36
- 241000700605 Viruses Species 0.000 claims description 71
- 210000004072 lung Anatomy 0.000 claims description 36
- 230000004224 protection Effects 0.000 claims description 32
- 241000588832 Bordetella pertussis Species 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 101150103308 ampG gene Proteins 0.000 claims description 18
- 230000002238 attenuated effect Effects 0.000 claims description 12
- 230000002733 dermonecrotic effect Effects 0.000 claims description 10
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 7
- 241000588807 Bordetella Species 0.000 abstract description 57
- 241000712461 unidentified influenza virus Species 0.000 abstract description 54
- 229960005486 vaccine Drugs 0.000 abstract description 46
- 241000124008 Mammalia Species 0.000 abstract description 40
- 208000015181 infectious disease Diseases 0.000 abstract description 29
- 241000699670 Mus sp. Species 0.000 description 114
- 239000002671 adjuvant Substances 0.000 description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 40
- 241000894006 Bacteria Species 0.000 description 38
- 201000010099 disease Diseases 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 34
- 230000003612 virological effect Effects 0.000 description 33
- 102000004127 Cytokines Human genes 0.000 description 26
- 108090000695 Cytokines Proteins 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 26
- 238000011282 treatment Methods 0.000 description 25
- 230000036039 immunity Effects 0.000 description 23
- 239000000427 antigen Substances 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 241000712431 Influenza A virus Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 241000282412 Homo Species 0.000 description 18
- 230000008506 pathogenesis Effects 0.000 description 18
- 239000002245 particle Substances 0.000 description 17
- 229930182490 saponin Natural products 0.000 description 17
- 150000007949 saponins Chemical class 0.000 description 17
- 235000017709 saponins Nutrition 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 230000001665 lethal effect Effects 0.000 description 16
- -1 oxyhydroxides) Chemical class 0.000 description 16
- 230000009385 viral infection Effects 0.000 description 16
- 108010074328 Interferon-gamma Proteins 0.000 description 15
- 231100000518 lethal Toxicity 0.000 description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 102000019034 Chemokines Human genes 0.000 description 11
- 108010012236 Chemokines Proteins 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 230000009885 systemic effect Effects 0.000 description 11
- 239000003053 toxin Substances 0.000 description 11
- 231100000765 toxin Toxicity 0.000 description 11
- 108700012359 toxins Proteins 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 206010035664 Pneumonia Diseases 0.000 description 10
- 206010035742 Pneumonitis Diseases 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 210000004443 dendritic cell Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 231100000636 lethal dose Toxicity 0.000 description 10
- 231100000252 nontoxic Toxicity 0.000 description 10
- 230000003000 nontoxic effect Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 9
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 206010064097 avian influenza Diseases 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000001018 virulence Effects 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 201000005702 Pertussis Diseases 0.000 description 8
- 230000029662 T-helper 1 type immune response Effects 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 230000006978 adaptation Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000000770 proinflammatory effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 230000005100 tissue tropism Effects 0.000 description 8
- 208000031648 Body Weight Changes Diseases 0.000 description 7
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 7
- 208000002979 Influenza in Birds Diseases 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 101150104836 Ptx gene Proteins 0.000 description 7
- 210000001132 alveolar macrophage Anatomy 0.000 description 7
- 230000004579 body weight change Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 229920000136 polysorbate Polymers 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 101150099497 dnt gene Proteins 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 230000009979 protective mechanism Effects 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000029069 type 2 immune response Effects 0.000 description 6
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 5
- 101710146739 Enterotoxin Proteins 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 5
- 102000002689 Toll-like receptor Human genes 0.000 description 5
- 108020000411 Toll-like receptor Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000000147 enterotoxin Substances 0.000 description 5
- 231100000655 enterotoxin Toxicity 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 5
- 229960005225 mifamurtide Drugs 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000001533 respiratory mucosa Anatomy 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 229940031439 squalene Drugs 0.000 description 5
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 206010050685 Cytokine storm Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000011510 Elispot assay Methods 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000227 bioadhesive Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 206010052015 cytokine release syndrome Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- APUIQTDTBPKWKE-RNPGEKFLSA-N (2r,6s)-6-[[(4r)-4-[[(2s)-2-[2-[[(1r,2s,3r,4r,5r)-4-acetamido-2-[(2s,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,8-dioxabicyclo[3.2.1]octan-3-yl]oxy]propanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-2-amino-7-[[(2r)-2-am Chemical compound O([C@@H]1[C@H]2CO[C@H](O2)[C@H](NC(C)=O)[C@H]1OC(C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@@H](N)C(O)=O)C(=O)NC(=O)[C@H](N)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O APUIQTDTBPKWKE-RNPGEKFLSA-N 0.000 description 3
- 241000588779 Bordetella bronchiseptica Species 0.000 description 3
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010053172 Fatal outcomes Diseases 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000004721 adaptive immunity Effects 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000004520 cell wall skeleton Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000011331 genomic analysis Methods 0.000 description 3
- HOPZBJPSUKPLDT-UHFFFAOYSA-N imidazo[4,5-h]quinolin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=C1 HOPZBJPSUKPLDT-UHFFFAOYSA-N 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 230000031261 interleukin-10 production Effects 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000003232 mucoadhesive effect Effects 0.000 description 3
- 230000016379 mucosal immune response Effects 0.000 description 3
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 210000001706 olfactory mucosa Anatomy 0.000 description 3
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000000277 virosome Substances 0.000 description 3
- 239000000304 virulence factor Substances 0.000 description 3
- 230000007923 virulence factor Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- 241000588780 Bordetella parapertussis Species 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000219287 Saponaria Species 0.000 description 2
- 230000033540 T cell apoptotic process Effects 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 238000012382 advanced drug delivery Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960001212 bacterial vaccine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000014564 chemokine production Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000005427 lymphocyte apoptotic process Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940066429 octoxynol Drugs 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QGKBSGBYSPTPKJ-UZMKXNTCSA-N 2,6-di-o-methyl-β-cyclodextrin Chemical compound COC[C@H]([C@H]([C@@H]([C@H]1OC)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O3)[C@H](O)[C@H]2OC)COC)O[C@@H]1O[C@H]1[C@H](O)[C@@H](OC)[C@@H]3O[C@@H]1COC QGKBSGBYSPTPKJ-UZMKXNTCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 101710110818 Dermonecrotic toxin Proteins 0.000 description 1
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 108010052014 Liberase Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 101500025613 Mus musculus Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 235000008981 Smilax officinalis Nutrition 0.000 description 1
- 240000002493 Smilax officinalis Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000008382 alveolar damage Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000013427 histology analysis Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008249 pharmaceutical aerosol Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008817 pulmonary damage Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to fields of microbiology and virology.
- Influenza A virus is both the best characterized and the most serious threat to public health, capable of inducing massive epidemics or pandemics. This virus is also highly variable antigenically, making effective vaccine production difficult.
- a vaccine to influenza would be one of the most efficacious, safe, nontoxic, and economical weapons to prevent disease and to control the spread of the disease.
- the primary aim of vaccination is to activate the adaptive specific immune response, primarily to generate B and T lymphocytes against antigen(s) associated with the disease or the disease agent.
- vaccines against influenza are available and primarily consist of inactivated vaccines. These vaccines can comprise two type A antigens (e.g., H1N1 and H3N2) and one type B antigen.
- the available vaccines typically include whole virion, split-product, and subunit vaccines. Generally, these vaccines are effective in up to 90% of vaccinated individuals if the vaccines closely match the identity of the emerging epidemic. However, they need to be updated each year to keep pace with antigenic drift of the influenza virus.
- LAIV live attenuated intranasal vaccine
- the invention addresses these and other problems in the influenza vaccine field by providing a vaccine and composition that elicits an immune response against one or more influenza strains using a mutated Bordetella strain as the active principle agent.
- the related art describes various types of vaccines and compositions using Bordetella strains (WO2007104451 and WO2003102170) to induce immune responses against, e.g., Bordetella bacteria capable of causing whooping cough in humans; however the art fails to disclose methods or compositions for eliciting an immune response to an influenza virus in a mammal using the methods, compositions, and/or vaccines of the invention.
- Bordetella strains WO2007104451 and WO2003102170
- the invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal.
- the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
- the invention provides a method of eliciting an immune response against an influenza virus in a mammal, comprising: administering a mutated Bordetella strain to the mammal, wherein the strain comprises a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene.
- the Bordetella strain comprises a Bordetella pertussis strain.
- the wild-type Bordetella strain ampG gene is replaced by an E. coli ampG gene.
- the mutation of the ptx gene comprises the substitution of an amino acid involved in substrate binding and/or an amino acid involved in catalysis.
- the substitution of the amino acid involved in substrate binding comprises R9K and the substitution of the amino acid involved in catalysis comprises E129G.
- the Bordetella strain comprises a triple mutant strain. In some such aspects, the Bordetella strain comprises a BPZE1 strain. In other such aspects, the Bordetella strain is attenuated. In some aspects, the Bordetella strain comprises a live strain. In other aspects, the Bordetella strain does not comprise a heterologous gene other than the heterologous ampG gene. In some aspects, the Bordetella strain does not comprise a heterologous expression platform to carry heterologous antigens to the respiratory mucosa of the mammal.
- the methods further comprise the prevention or treatment of the influenza infection in the mammal.
- the Bordetella strain is administered prior to the influenza infection. In some such aspects, the Bordetella strain is administered about 6 weeks or more prior to the influenza infection. In other such aspects, the Bordetella strain is administered about 12 weeks or more prior to the influenza infection.
- the influenza virus comprises H3 or H1. In other aspects, the influenza virus comprises N2 or N1.
- the influenza virus comprises H3 and N2. In other aspects, the influenza virus comprises H1 and N1. In some aspects, the immune response comprises a Th1 immune response. In some aspects, the strain is administered to the mammal by subcutaneous (s.c.), intradermal (i.d.), intramuscular (i.m.), intravenous (i.v.), oral, or intranasal administration; or by injection or by inhalation. In other aspects, the strain is administered intranasally. In some other aspects, the strain is administrated to a mammal in need of protective immunity against the influenza infection. In some aspects the mammal is a child. In some aspects, the strain is administered once in a single dose. In some aspects, the strain is administered in more than one dose.
- the strain is administered twice in two doses. In other aspects, the two doses are administered about 3 weeks apart. In some aspects, a level of protection against the influenza infection is more than about 60%. In other aspects, a level of protection against the influenza infection is more than about 50%. In some aspects, the mammal is a human.
- the invention provides methods of eliciting a protective immune response against an H3N2 influenza virus in a human, comprising: intranasally administering a live and attenuated BPZE1 strain to the human prior to infection of the human by the H3N2 influenza virus, wherein the strain does not comprise a heterologous expression platform to carry heterologous antigens to the respiratory mucosa of the human.
- the invention provides methods of eliciting an immune response against an influenza virus in a human, comprising: administering a live Bordetella strain to the human, wherein the strain does not comprise a heterologous expression platform to carry heterologous antigens to the respiratory mucosa of the human.
- the invention provides methods of protecting a mammal against a disease caused by an influenza infection, comprising: administering to the mammal a mutated Bordetella strain comprising a mutated ptx gene, a deleted or mutated dnt gene, and a heterologous ampG gene.
- the invention provides a protective immunity against an influenza infection, comprising: administering to the mammal a mutated Bordetella strain comprising a mutated ptx gene, a deleted or mutated dnt gene, and a heterologous ampG gene.
- the invention provides a composition for treating or preventing an influenza infection in a mammal, comprising: a mutated Bordetella strain, wherein the strain comprises a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene.
- the Bordetella strain comprises a Bordetella pertussis strain.
- the wild-type Bordetella strain ampG gene is replaced by an E. coli ampG gene.
- the mutation of the ptx gene comprises the substitution of an amino acid involved in substrate binding and/or an amino acid involved in catalysis.
- the substitution of the amino acid involved in substrate binding comprises R9K and the substitution of the amino acid involved in catalysis comprises E129G.
- the Bordetella strain comprises a triple mutant strain.
- the invention provides a vaccine comprising a composition of the invention for treating or preventing the influenza infection in the mammal.
- the vaccine comprises a Bordetella strain composition described herein.
- the vaccine is formulated for intranasal administration.
- the invention provides a Bordetella strain identified by accession number CNCM 1-3585.
- the invention provides a Bordetella strain identified by accession number V09/009169.
- FIGS. 1 A and 1 B show protection rate of BPZE1-treated mice against lethal challenge with mouse-adapted H3N2 virus.
- Adult Balb/c mice were nasally administered with 5 ⁇ 10 6 cfu of BPZE1 bacteria and challenged either 3 weeks (solid square) or 6 weeks (solid triangle) later with a lethal dose (2LD50) of mouse-adapted H3N2 virus.
- Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid lozenge). 10 animals per group were assessed. Results are representative of three independent experiments.
- FIG. 2 shows protection rates against lethal challenge with mouse-adapted H3N2 virus in mice treated with dead versus live BPZE1 bacteria.
- Adult Balb/c mice were nasally administered with 5 ⁇ 10 6 cfu of live (solid triangle) or dead (solid square) BPZE1 bacteria, and challenged 6 weeks later with a lethal dose (2LD50) of mouse-adapted H3N2 virus.
- Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid lozenge). 10 animals per group were assessed. Results are representative of two independent experiments.
- FIGS. 3 A and 3 B show protection rate against lethal challenge with mouse-adapted H3N2 virus in mice treated twice with live BPZE1 bacteria.
- Adult Balb/c mice were nasally administered twice at a 4-week interval with 5 ⁇ 10 6 cfu of BPZE1 bacteria (solid square) and challenged 4 weeks later with a lethal dose (2LD50) of mouse-adapted H3N2 virus.
- Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid lozenge). 10 animals per group were assessed. Results are representative of two independent experiments.
- FIGS. 4 A and 4 B show protection rate of BPZE1-treated mice against lethal challenge with H1N1 influenza A virus.
- Adult Balb/c mice were nasally administered three times at 4-week and 3-week intervals (solid triangle) with 5 ⁇ 10 6 cfu of live BPZE1 bacteria.
- the animals were challenged with a lethal dose (4 LD50) of A/PR/8/34 (H1N1) influenza A virus 2 weeks after the last BPZE1 treatment.
- Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid lozenge). 10 animals per group were assessed. Results are representative of 2 independent experiments.
- FIG. 5 shows viral load quantification in the lungs of protected versus non-protected mice.
- Adult Balb/c mice were nasally administered twice at a 4-week interval with 5 ⁇ 10 6 cfu of live BPZE1 bacteria and challenged 4 weeks later with a lethal dose (2LD50) of mouse-adapted H3N2 virus.
- Five animals per group were sacrificed 3 days post-viral challenge, their lungs were harvested and individually processed for in vitro determination of TCID 50 upon infection of MDCK cells. The viral load was compared with that obtained in non-treated mice. Results are representative of 3 independent experiments.
- FIGS. 6 A and 6 B show lung histology and cellular infiltrates and CD3 + T cell population in the lungs in BPZE1-treated versus non-treated mice after lethal viral challenge.
- Adult Balb/c mice were nasally administered with 5 ⁇ 10 6 cfu of live BPZE1 bacteria and challenged 6 weeks later with a lethal dose (2LD50) of mouse-adapted H3N2 virus.
- 2LD50 lethal dose
- mice Three days post-viral challenge, mice were euthanized and their lungs were individually processed for histology analysis (A) or broncho-alveolar lavages for analysis of the cellular infiltrates (B).
- Infected control mice displayed severe inflammation, pulmonary edema (black arrow) and severe necrotizing bronchitis with necrotic cell debris (open arrow).
- Infected BPZE1-treated mice showed only minimal inflammation and airway damage, and mild peribronchular damage. Representative fields are shown. Results were equivalent in more than 40 fields analyzed per group (>5 fields/section, 2 sections/mouse and 4 mice/group).
- Legend B a, na ⁇ ve mice non-challenged; b, na ⁇ ve mice challenged with H3N2 virus; c, BPZE1-treated mice non-challenged; d, BPZE1-treated mice challenged with H3N2 virus. Four animals per time point per group were individually assessed.
- Results are representative of two independent experiments.
- C FACS analysis of the CD3 + T cell population in the mice lungs. 3 days or 5 days after lethal H3N2 influenza virus challenge, non-treated control mice and mice treated twice with BPZE1 were euthanized and CD3 + T cell population in their lungs were analyzed by flow cytometry. Four animals per time point per group were individually assessed. Results are expressed in percentage of CD3 + T cells in the total lung cell population. mean ⁇ SD.
- na ⁇ ve mice non-challenged na ⁇ ve mice non-challenged
- b BPZE1-treated mice non-challenged
- c na ⁇ ve mice challenged with H3N2 virus and sacrificed 3 days later
- d BPZE1-treated mice challenged with H3N2 virus and sacrificed 3 days later
- e na ⁇ ve mice challenged with H3N2 virus and sacrificed 5 days later
- f BPZE1-treated mice challenged with H3N2 virus and sacrificed 5 days later.
- *** p ⁇ 0.001.
- FIGS. 7 A- 7 L show pro- and anti-inflammatory cytokine and chemokine profiles in the BPZE1-treated versus non-treated mice after lethal H3N2 viral challenge.
- Adult Balb/c mice were nasally administered twice at a 4-week interval with 5 ⁇ 10 6 cfu of live BPZE1 bacteria and were challenged with a lethal dose (2LD50) of mouse-adapted H3N2 virus 4 weeks after the last administration.
- 2LD50 lethal dose
- mice per group and per time point were sacrificed and broncho-alveolar lavages fuilds (BALFs) were collected. 14 inflammation-related cytokines and chemokines were measured in each individual BALF sample.
- BALFs broncho-alveolar lavages fuilds
- FIGS. 8 A- 8 C show role of the B. pertussis -specific immunity in the cross-protection.
- A Naive (open triangle) or anti-H3N2 (solid circle) or anti-BPZE1 (open circle) immune serum was ip. injected to adult na ⁇ ve Balb/c mice one day prior to lethal challenge (2LD50) with mouse-adapted H3N2 virus. Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid triangle). 10 animals per group were assessed.
- B & (C).
- mice were nasally administered with 5 ⁇ 10 6 cfu of live BPZE1 bacteria and 6 weeks later the animals were euthanized and their spleens were harvested. Pooled (B) or individual (C) splenocytes from 6 animals were stimulated with either BPZE1 lysate or heat-inactivated H3N2 virus particles. 3H-thymidine incorporation (B) and IFN- ⁇ ELISPOT assay (C) were performed as described below. Representative of two different experiments, both showed similar results; mean ⁇ SD; *, p ⁇ 0.05, ***, p ⁇ 0.001.
- the invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing influenza infection in a mammal.
- the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
- PTX refers to pertussis toxin, which synthesizes and secretes an ADP-ribosylating toxin.
- PTX is comprised of five different subunits (named S1-S5) with each complex containing two copies of S4.
- the subunits are arranged in an A-B structure.
- the A component is enzymatically active and is formed from the S1 subunit, while the B component is the receptor binding portion and is made up of subunits S2-S5.
- DNT pertussis dermonecrotic toxin, which is a heat labile toxin that can induce localized lesions in mice and other laboratory animals when it is injected intradermally.
- TCT refers to tracheal cytotoxin, which is a virulence factor synthesized by Bordetellae.
- TCT is a peptidoglycan fragment and has the ability to induce interleukin-1 production and nitric oxide synthase. It has the ability to cause stasis of cilia and has lethal effects on respiratory epithelial cells.
- the term “attenuated” refers to a weakened, less virulent Bordetella strain that is capable of stimulating an immune response and creating protective immunity, but does not generally cause illness.
- rapidly protective immunity means that immunity against Bordetella is conferred in a short time after administration of the mutated Bordetella strain of the invention.
- Bordetella strain includes strains from Bordetella pertussis, Bordetella parapertussis , and Bordetella bronchiseptica.
- child is meant to be a person or a mammal between 0 months and 18 years of age.
- Treating refers to any indicia of success in the treatment or amelioration or prevention of the disease, condition, or disorder, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the disease condition more tolerable to the patient; slowing in the rate of degeneration or decline; or making the final point of degeneration less debilitating.
- the treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of an examination by a physician.
- the term “treating” includes the administration of the compounds or agents of the invention to prevent or delay, to alleviate, or to arrest or inhibit development of the symptoms or conditions associated with a disease, condition or disorder as described herein.
- Treating” or “treatment” using the methods of the invention includes preventing the onset of symptoms in a subject that can be at increased risk of a disease or disorder associated with a disease, condition or disorder as described herein, but does not yet experience or exhibit symptoms, inhibiting the symptoms of a disease or disorder (slowing or arresting its development), providing relief from the symptoms or side effects of a disease (including palliative treatment), and relieving the symptoms of a disease (causing regression).
- Treatment can be prophylactic (to prevent or delay the onset of the disease, or to prevent the manifestation of clinical or subclinical symptoms thereof) or therapeutic suppression or alleviation of symptoms after the manifestation of the disease or condition.
- Conscomitant administration of a known drug (or other compound) with the composition of the invention means administration of the drug (or other compound) together with the composition at such time that both the known drug (or other compound) will have a therapeutic effect or diagnostic effect. Such concomitant administration can involve concurrent (i.e., at the same time), prior, or subsequent administration of the drug (or other compound) with respect to the administration of a composition of the invention.
- a person of ordinary skill in the art would have no difficulty determining the appropriate timing, sequence, and dosages of administration for particular drugs (or other compounds) together with compositions of the invention.
- protection and “prevention” are used herein interchangeably and mean that an infection by influenza is impeded.
- “Prophylaxis vaccine” means that this vaccine prevents influenza infection upon future exposure.
- immunological composition or “composition” means that the composition can induce an immune response and is therefore antigenic.
- immune response means any reaction by the immune system. These reactions include the alteration in the activity of an organism's immune system in response to an antigen and can involve, for example, antibody production, induction of cell-mediated immunity, complement activation, or development of immunological tolerance.
- disease has the meaning generally known and understood in the art and comprises any abnormal condition in the function or well being of a host individual.
- a diagnosis of a particular disease by a healthcare professional can be made by direct examination and/or consideration of results of one or more diagnostic tests.
- live vaccine composition refers to a composition comprising a strain of live Bordetella bacteria that provides at least partial protective immunity against influenza.
- oral refers to administration of a compound or composition to an individual by a route or mode along the alimentary canal.
- oral routes of administration of a composition include, without limitation, swallowing liquid or solid forms of a vaccine composition from the mouth, administration of a vaccine composition through a nasojejunal or gastrostomy tube, intraduodenal administration of a vaccine composition, and rectal administration, e.g., using suppositories that release a live bacterial vaccine strain described herein.
- Topical administration refers to the application of a pharmaceutical agent to the external surface of the skin or the mucous membranes (including the surface membranes of the nose, lungs and mouth), such that the agent crosses the external surface of the skin or mucous membrane and enters the underlying tissues. Topical administration can result in a limited distribution of the agent to the skin and surrounding tissues or, when the agent is removed from the treatment area by the bloodstream, systemic distribution of the agent.
- the agent is delivered by transdermal delivery, e.g., using a transdermal patch.
- Transdermal delivery refers to the diffusion of an agent across the skin (stratum corneum and epidermis), which acts as a barrier few agents are able to penetrate.
- the dermis is permeable to absorption of many solutes and drugs, and topical administration therefor occurs more readily through skin which is abraded or otherwise stripped of the epidermis to expose the dermis.
- Absorption through intact skin can be enhanced by combining the active agent with an oily vehicle (e.g., creams, emollients, penetration enhancers, and the like, as described, e.g., in Remington's Pharmaceutical Sciences, current edition, Gennaro et al., eds.) prior to application to the skin (a process known as inunction).
- an oily vehicle e.g., creams, emollients, penetration enhancers, and the like, as described, e.g., in Remington's Pharmaceutical Sciences, current edition, Gennaro et al., eds.
- nasal administration refers to any form of administration whereby an active ingredient is propelled or otherwise introduced into the nasal passages of a subject so that it contacts the respiratory epithelium of the nasal cavity, from which it is absorbed into the systemic circulation.
- Nasal administration can also involve contacting the olfactory epithelium, which is located at the top of the nasal cavity between the central nasal septum and the lateral wall of each main nasal passage. The region of the nasal cavity immediately surrounding the olfactory epithelium is free of airflow. Thus, specialized methods must typically be employed to achieve significant absorption across the olfactory epithelium.
- a pharmaceutical aerosol of the invention contains a therapeutically active compound, which can be dissolved, suspended, or emulsified in a mixture of a fluid carrier and a propellant.
- the aerosol can be in the form of a solution, suspension, emulsion, powder, or semi-solid preparation. Aerosols of the invention are intended for administration as fine, solid particles or as liquid mists via the respiratory tract of a patient.
- propellants can be utilized including, but not limited to, hydrocarbons or other suitable gases.
- Aerosols of the invention can also be delivered with a nebulizer, which generates very fine liquid particles of substantially uniform size within a gas.
- a liquid containing the active compound is dispersed as droplets, which can be carried by a current of air out of the nebulizer and into the respiratory tract of the patient.
- ameliorating refers to any therapeutically beneficial result in the treatment of a disease state, e.g., an influenza-related disease state, including prophylaxis, lessening in the severity or progression, remission, or cure thereof.
- the phrase “well tolerated” refers to the absence of adverse changes in health status that occur as a result of the treatment and would affect treatment decisions.
- “Synergistic interaction” refers to an interaction in which the combined effect of two or more agents is greater than the algebraic sum of their individual effects.
- in vitro refers to processes that occur in a living cell growing separate from a living organism, e.g., growing in tissue culture.
- in vivo refers to processes that occur in a living organism.
- mammal as used herein includes both humans and non-humans and include but is not limited to humans, non-human primates, canines, felines, murines, bovines, equines, and porcines.
- sufficient amount means an amount sufficient to produce a desired effect, e.g., an amount sufficient to modulate protein aggregation in a cell.
- therapeutically effective amount is an amount that is effective to ameliorate a symptom of a disease.
- a therapeutically effective amount can be a “prophylactically effective amount” as prophylaxis can be considered therapy.
- the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion.
- a process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but can include other elements not expressly listed or inherent to such process or method.
- “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
- “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ⁇ 20% or ⁇ 10%, more preferably ⁇ 5%, even more preferably ⁇ 1%, and still more preferably ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
- influenza virus infection There are three types of influenza viruses that can be targeted by the invention: Influenza A, B, and C.
- Influenza type A viruses are divided into subtypes based on two proteins on the surface of the virus. These proteins are termed hemagglutinin (H) and neuraminidase (N).
- Influenza A viruses are divided into subtypes based on these two proteins.
- Influenza A viruses include A(H1N1) and A(H3N2), both of which are examples of influenza viruses that can be targeted by the invention for treatment or prevention in a mammal Diseases and symptoms typically caused by influenza virus infection can include: fever, coughing, sneezing, aches, fatigue, headache, watery eyes, nasal congestion, and abdominal pain.
- the invention can be used to treat or prevent these diseases.
- the invention provides a mutated Bordetella strain that can be used as an immunogenic composition or a vaccine to elicit an immune response in a mammal.
- the mutated Bordetella strain contains a mutated ptx gene, a deleted or mutated dnt gene, and a heterologous ampG gene.
- the heterologous ampG gene product can reduce in large quantities the amount of tracheal cytotoxin that is produced.
- the strain is BPZE1.
- the starting strain which is mutated can be any Bordetella strain including Bordetella pertussis, Bordetella parapertussis , and Bordetella bronchiseptica .
- the starting strain used to obtain the mutated Bordetella strain is B. pertussis .
- the strain is a triple mutant Bordetella strain.
- the Bordetella strain is identified by accession number CNCM 1-3585.
- the Bordetella strain is identified by accession number V09/009169.
- the invention is not limited to only the mutants described above.
- Other additional mutations can be undertaken such as adenylate cyclase (AC) deficient mutants, lipopolysaccharide (LPS) deficient mutants, filamentous hemagglutinin (FHA), and any of the bvg-regulated components.
- AC adenylate cyclase
- LPS lipopolysaccharide
- FHA filamentous hemagglutinin
- a mutated Bordetella strain of the invention can begin with replacing the Bordetella ampG gene in the strain with a heterologous ampG gene.
- Any heterologous ampG gene known in the art can be used in the invention. Examples of these can include all gram-negative bacteria that release very small amounts of peptidoglycan fragments into the medium per generation. Examples of gram-negative bacteria include, but are not limited to: Escherichia coli, Salmonella, Enterobacteriaceae, Pseudomonas, Moraxella, Helicobacter, Stenotrophomonas, Legionella , and the like.
- the amount of tracheal cytoxin (TCT) produced in the resulting strain expresses less than 1% residual TCT activity.
- the amount of TCT toxin expressed by the resulting strain is between about 0.6% to 1% residual TCT activity or about 0.4% to 3% residual TCT activity or about 0.3% to 5% residual TCT activity.
- PTX is a major virulence factor responsible for the systemic effects of B. pertussis infections, as well as one of the major protective antigens. Due to its properties, the natural ptx gene can be replaced by a mutated version so that the enzymatically active moiety 51 codes for an enzymatically inactive toxin, but the immunogenic properties of the pertussis toxin are not affected. This can be accomplished by replacing the arginine (Arg) at position 9 of the sequence with a lysine (Lys) (R9K). Furthermore, a glutamic acid (Glu) at position 129 can be replaced with a glycine (GIy) (E129G).
- Arg arginine
- Glu glutamic acid
- E129G glycine
- allelic exchange can first be used to delete the ptx operon and then to insert a mutated version.
- the dnt gene can be removed from the Bordetella strain using allelic exchange. Besides the total removal, the enzymatic activity can also be inhibited by a point mutation. Since DNT is constituted by a receptor-binding domain in the N-terminal region and a catalytic domain in the C-terminal part, a point mutation in the dnt gene to replace Cys-1305 to Ala-1305 inhibits the enzyme activity of DNT (Kashimoto T., Katahira J, Cornejo W R, Masuda M, Fukuoh A, Matsuzawa T, Ohnishi T, Horiguchi Y. (1999) Identification of functional domains of Bordetella dermonecrotizing toxin. Infect. Immun. 67: 3727-32.).
- the open reading frame of a gene can be interrupted by insertion of a genetic sequence or plasmid. This method is also contemplated in the invention. Other methods of generating mutant strains are generally well known in the art.
- the mutated strain is called a BPZE1 strain and has been deposited with the Collection Nationale de Cultures de Microorganismes (CNCM) in Paris, France under the Budapest Treaty on Mar. 9, 2006 and assigned the number CNCM 1-3585.
- the mutations introduced into BPZE1 generally result in attenuation, but also allow the bacteria to colonize and persist.
- the invention provides BPZE1, which can induce mucosal immunity and systemic immunity when administered to a mammal in need thereof.
- a BPZE1 recombinant strain was constructed which expresses three copies of M2e peptide.
- M2e is the extracellular portion of the M2 protein from influenza virus. It is highly conserved among all influenza A viruses and has been shown to induce an antibody-mediated protection against influenza A viruses.
- the recombinant M2e-producing BPZE1 strain can trigger (for example, upon nasal administration of the live bacteria) substantial anti-M2e antibody responses (local and systemic), allowing a significant protection against H1N1 and H3N2 challenge comparable to the BPZE1 bacteria alone.
- the mutated Bordetella strains of the invention can be used in immunogenic compositions for the treatment or prevention of influenza virus infections.
- immunogenic compositions are useful to raise an immune response, either an antibody response and or a T cell response in mammals.
- the T cell response can be such that it protects a mammal against influenza infection or against its consequences/diseases/symptoms.
- the mutated Bordetella strains of the invention can be used as live strains in vaccines or immunogenic compositions.
- the live strains are used for nasal administration, while the chemically- or heat killed strains can be used for systemic or mucosal administration.
- the stains are attenuated.
- the strains do not include any heterologous genes other than the heterologous ampG gene described above.
- the strains do not include a heterologous expression platform (See, e.g., WO2007104451).
- heterologous expression platforms carry heterologous antigens.
- the heterologous expression platform can be used to deliver the heterologous antigens to the respiratory mucosa of a mammal.
- compositions of the invention can be administered in conjunction with other immunoregulatory agents, including adjuvants.
- adjuvant refers to a compound or mixture that enhances an immune response.
- compositions can include an adjuvant.
- adjuvants for use with the invention can include, but are not limited to, one or more of the following set forth below:
- Mineral containing compositions suitable for use as adjuvants in the invention include mineral salts, such as aluminum salts and calcium salts.
- the invention includes mineral salts such as hydroxides (e.g., oxyhydroxides), phosphates (e.g., hydroxyphosphates, orthophosphates), sulfates, and the like (e.g., see chapters 8 & 9 of Vaccine Design . . . (1995) eds. Powell & Newman ISBN: 030644867X.
- the mineral containing compositions can also be formulated as a particle of metal salt (WO/0023105).
- Aluminum salts can be included in compositions of the invention such that the dose of Al 3 + is between 0.2 and 1.0 mg per dose.
- Oil-emulsion compositions suitable for use as adjuvants in the invention can include squalene-water emulsions, such as MF59 (5% Squalene, 0.5% TWEEN® 80, and 0.5% SPAN® 85, formulated into submicron particles using a microfluidizer). See, e.g., WO90/14837. See also, Podda, “The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine”, Vaccine 19: 2673-2680, 2001.
- adjuvants for use in the compositions are submicron oil-in-water emulsions.
- submicron oil-in-water emulsions for use herein include squalene/water emulsions optionally containing varying amounts of MTP-PE, such as a submicron oil-in-water emulsion containing 4-5% w/v squalene, 0.25-1.0% w/v TWEEN® 80 (polyoxyelthylenesorbitan monooleate), and/or 0.25-1.0% SPAN® 85 (sorbitan trioleate), and, optionally, N-acetylmuramyl-L-alanyl-D-isogluatminyl-L-alanine-2-(F-2′-dipalmitoyl-s-n-glycero-3-huydroxyphosphophoryloxy)-ethylamine (MTP-PE), for example, the submicron oil-in-water emul
- MF59 can contain 4-5% w/v Squalene (e.g., 4.3%), 0.25-0.5% w/v TWEEN® 80, and 0.5% w/v SPAN® 85 and optionally contains various amounts of MTP-PE, formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA).
- MTP-PE can be present in an amount of about 0-500 ⁇ g/dose, or 0-250 ⁇ g/dose, or 0-100 ⁇ g/dose.
- CFA Complete Freund's adjuvant
- IFA incomplete Freund's adjuvant
- Saponin formulations can also be used as adjuvants in the invention.
- Saponins are a heterologous group of sterol glycosides and triterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species. Saponin from the bark of the Quillaia saponaria Molina tree have been widely studied as adjuvants. Saponin can also be commercially obtained from Smilax ornata (sarsaprilla), Gypsophilla paniculata (brides veil), and Saponaria officianalis (soap root).
- Saponin adjuvant formulations can include purified formulations, such as QS21, as well as lipid formulations, such as Immunostimulating Complexs (ISCOMs; see below).
- Saponin compositions have been purified using High Performance Thin Layer Chromatography (HPLC) and Reversed Phase High Performance Liquid Chromatography (RP-HPLC). Specific purified fractions using these techniques have been identified, including QS7, QS17, QS18, QS21, QH-A, QH-B and QH-C. A method of production of QS21 is disclosed in U.S. Pat. No. 5,057,540. Saponin formulations can also comprise a sterol, such as cholesterol (see WO96/33739).
- ISCOMs typically also include a phospholipid such as phosphatidylethanolamine or phosphatidylcholine.
- a phospholipid such as phosphatidylethanolamine or phosphatidylcholine.
- Any known saponin can be used in ISCOMs.
- an ISCOM can include one or more of Quil A, QHA and QHC.
- ISCOMs are further described in EP0109942, WO96/11711, and WO96/33739.
- the ISCOMS can be devoid of additional detergent. See WO00/07621.
- VLPs Virosomes and Virus Like Particles
- Virosomes and Virus Like Particles can also be used as adjuvants in the invention.
- These structures generally contain one or more proteins from a virus optionally combined or formulated with a phospholipid. They are generally non-pathogenic, non-replicating and generally do not contain any of the native viral genome.
- the viral proteins can be recombinantly produced or isolated from whole viruses.
- viral proteins suitable for use in virosomes or VLPs include proteins derived from influenza virus (such as HA or NA), Hepatitis B virus (such as core or capsid proteins), Hepatitis E virus, measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth Disease virus, Retrovirus, Norwalk virus, human Papilloma virus, HIV, RNA-phages, QB-phage (such as coat proteins), GA-phage, fr-phage, AP205 phage, and Ty (such as retrotransposon Ty protein pl).
- influenza virus such as HA or NA
- Hepatitis B virus such as core or capsid proteins
- Hepatitis E virus measles virus
- Sindbis virus Rotavirus
- Foot-and-Mouth Disease virus Retrovirus
- Norwalk virus Norwalk virus
- human Papilloma virus HIV
- RNA-phages such as coat proteins
- GA-phage f-phage
- fr-phage AP205
- Adjuvants suitable for use in the invention include bacterial or microbial derivatives such as:
- Such derivatives include Monophosphoryl lipid A (MPL) and 3-O-deacylated MPL (3 dMPL).
- 3 dMPL is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains.
- An example of a “small particle” form of 3 De-O-acylated monophosphoryl lipid A is disclosed in EP 0 689 454.
- Such “small particles” of 3 dMPL are small enough to be sterile filtered through a 0.22 micron membrane (see EP 0 689 454).
- Other non-toxic LPS derivatives include monophosphoryl lipid A mimics, such as aminoalkyl glucosaminide phosphate derivatives e.g., RC-529. See Johnson et al., Bioorg Med Chem Lett 9: 2273-2278, 1999.
- Lipid A derivatives can include derivatives of lipid A from Escherichia coli such as OM-174.
- OM-174 is described for example in Meraldi et al., “OM-174, a New Adjuvant with a Potential for Human Use, Induces a Protective Response with Administered with the Synthetic C-Terminal Fragment 242-310 from the circumsporozoite protein of Plasmodium berghei”, Vaccine 21: 2485-2491, 2003; and Pajak, et al., “The Adjuvant OM-174 induces both the migration and maturation of murine dendritic cells in vivo”, Vaccine 21: 836-842, 2003.
- Immunostimulatory oligonucleotides suitable for use as adjuvants in the invention can include nucleotide sequences containing a CpG motif (a sequence containing an unmethylated cytosine followed by guanosine and linked by a phosphate bond). Bacterial double stranded RNA or oligonucleotides containing palindromic or poly(dG) sequences have also been shown to be immunostimulatory.
- the CpG's can include nucleotide modifications/analogs such as phosphorothioate modifications and can be double-stranded or single-stranded.
- the guanosine can be replaced with an analog such as 2′-deoxy-7-deazaguanosine. See Kandimalla, et al., “Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles”, Nucleic Acids Research 31: 2393-2400, 2003; WO02/26757 and WO99/62923 for examples of analog substitutions.
- CpG oligonucleotides The adjuvant effect of CpG oligonucleotides is further discussed in Krieg, “CpG motifs: the active ingredient in bacterial extracts?”, Nature Medicine (2003) 9(7): 831-835; McCluskie, et al., “Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA”, FEMS Immunology and Medical Microbiology (2002) 32:179-185; WO98/40100; U.S. Pat. Nos. 6,207,646; 6,239,116 and 6,429,199.
- the CpG sequence can be directed to Toll-like receptor (TLR9), such as the motif GTCGTT or TTCGTT.
- TLR9 Toll-like receptor
- the CpG sequence can be specific for inducing a Th1 immune response, such as a CpG-A ODN, or it can be more specific for inducing a B cell response, such a CpG-B ODN.
- CpG-A and CpG-B ODNs are discussed in Blackwell, et al., “CpG-A-Induced Monocyte IFN-gamma-Inducible Protein-10 Production is Regulated by Plasmacytoid Dendritic Cell Derived IFN-alpha”, J. Immunol. 170: 4061-4068, 2003; Krieg, “From A to Z on CpG”, TRENDS in Immunology 23: 64-65, 2002, and WOO1/95935.
- the CpG oligonucleotide can be constructed so that the 5′ end is accessible for receptor recognition.
- two CpG oligonucleotide sequences can be attached at their 3′ ends to form “immunomers”.
- Kandimalla “Secondary structures in CpG oligonucleotides affect immunostimulatory activity”
- BBRC 306 948-95, 2003
- Kandimalla, et al. “Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic GpG DNAs”
- Bhagat et al. “CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents” BBRC 300: 853-861, 2003, and WO03/035836.
- Bacterial ADP-ribosylating toxins and detoxified derivatives thereof can be used as adjuvants in the invention.
- the toxin can be derived from E. coli (i.e., E. coli heat labile enterotoxin (LT)), cholera (CT), or pertussis (PTX).
- LT heat labile enterotoxin
- CT cholera
- PTX pertussis
- the use of detoxified ADP-ribosylating toxins as mucosal adjuvants is described in WO95/17211 and as parenteral adjuvants in WO98/42375.
- the adjuvant can be a detoxified LT mutant such as LT-K63, LT-R72, and LTR192G.
- ADP-ribosylating toxins and detoxified derivaties thereof, particularly LT-K63 and LT-R72, as adjuvants can be found in the following references, each of which is specifically incorporated by reference herein in their entirety: Beignon, et al., “The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enahnces the Ability of Peptide Antigens to Elicit CD4+T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin”, Infection and Immunity 70: 3012-3019, 2002; Pizza, et al., “Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants”, Vaccine 19: 2534-2541, 2001; Pizza, et al., “LTK63 and LTR72, two mucosal adjuvants ready for clinical trials” Int.
- Numerical reference for amino acid substitutions is preferably based on the alignments of the A and B subunits of ADP-ribosylating toxins set forth in Domenighini et al., Mol. Microbiol 15: 1165-1167, 1995, specifically incorporated herein by reference in its entirety.
- Bioadhesives and mucoadhesives can also be used as adjuvants in the invention.
- Suitable bioadhesives can include esterified hyaluronic acid microspheres (Singh et al., J. Cont. Rele. 70:267-276, 2001) or mucoadhesives such as cross-linked derivatives of poly(acrylic acid), polyvinyl alcohol, polyvinyl pyrollidone, polysaccharides and carboxymethylcellulose. Chitosan and derivatives thereof can also be used as adjuvants in the invention. See, for example, WO99/27960.
- Microparticles can also be used as adjuvants in the invention.
- Microparticles i.e., a particle of about 100 nm to about 150 ⁇ m in diameter, or 200 nm to about 30 ⁇ m in diameter, or about 500 nm to about 10 ⁇ m in diameter
- materials that are biodegradable and/or non-toxic e.g., a poly(alpha-hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone, and the like
- a negatively-charged surface e.g., with SDS
- a positively-charged surface e.g., with a cationic detergent, such as CTAB
- liposome formulations suitable for use as adjuvants are described in U.S. Pat. Nos. 6,090,406, 5,916,588, and EP 0 626 169.
- Adjuvants suitable for use in the invention can also include polyoxyethylene ethers and polyoxyethylene esters. WO99/52549. Such formulations can further include polyoxyethylene sorbitan ester surfactants in combination with an octoxynol (WO01/21207) as well as polyoxyethylene alkyl ethers or ester surfactants in combination with at least one additional non-ionic surfactant such as an octoxynol (WO01/21152).
- polyoxyethylene ethers can include: polyoxyethylene-9-lauryl ether (laureth 9), polyoxyethylene-9-steoryl ether, polyoxytheylene-8-steoryl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, or polyoxyethylene-23-lauryl ether.
- PCPP Polyphosphazene
- PCPP formulations for use as adjuvants are described, for example, in Andrianov et al., “Preparation of hydrogel microspheres by coacervation of aqueous polyphophazene solutions”, Biomaterials 19: 109-115, 1998, and Payne et al., “Protein Release from Polyphosphazene Matrices”, Adv. Drug. Delivery Review 31: 185-196, 1998.
- muramyl peptides suitable for use as adjuvants in the invention can include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-1-alanyl-d-isoglutamine (nor-MDP), and N-acetylmuramyl-1-alanyl-d-isoglutaminyl-1-alanine-2-(1′-2′-dipalmitoyl-s-n-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE).
- thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
- nor-MDP N-acetyl-normuramyl-1-alanyl-d-isoglutamine
- imidazoquinolone compounds suitable for use as adjuvants in the invention can include Imiquimod and its homologues, described further in Stanley, “Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential” Clin Exp Dermatol 27: 571-577, 2002 and Jones, “Resiquimod 3M”, Curr Opin Investig Drugs 4: 214-218, 2003.
- Human immunomodulators suitable for use as adjuvants in the invention can include cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, and the like), interferons (e.g., interferon-gamma), macrophage colony stimulating factor, and tumor necrosis factor.
- cytokines such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, and the like), interferons (e.g., interferon-gamma), macrophage colony stimulating factor, and tumor necrosis factor.
- adjuvant compositions can include:
- Aluminum salts and MF59 are examples of adjuvants for use with injectable influenza vaccines.
- Bacterial toxins and bioadhesives are examples of adjuvants for use with mucosally-delivered vaccines, such as nasal vaccines. All adjuvants noted above and others as generally known in the art to one of ordinary skill can be formulated for intranasal administration using techniques well known in the art.
- compositions of the invention can be formulated in pharmaceutical compositions. These compositions can comprise, in addition to one or more of the strains, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer, or other materials well known to those skilled in the art. Such materials should typically be non-toxic and should not typically interfere with the efficacy of the active ingredient.
- a pharmaceutically acceptable excipient e.g., oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, or intraperitoneal routes.
- compositions for oral administration can be in tablet, capsule, powder or liquid form.
- a tablet can include a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil, or synthetic oil. Physiological saline solution, dextrose, or other saccharide solution or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol can be included.
- the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity, and stability.
- a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity, and stability.
- isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, or Lactated Ringer's Injection.
- Preservatives, stabilisers, buffers, antioxidants, and/or other additives can be included, as required.
- Administration is preferably in a “therapeutically effective amount” or “prophylactically effective amount” (as the case can be, although prophylaxis can be considered therapy), this being sufficient to show benefit to the individual.
- a “therapeutically effective amount” or “prophylactically effective amount” as the case can be, although prophylaxis can be considered therapy
- the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of disease being treated. Prescription of treatment, e.g., decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in the latest edition of Remington's Pharmaceutical Science, Mack Publishing Company, Easton, PA (“Remington's”).
- compositions can be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
- compositions of the invention will generally be administered directly to a mammal
- Direct delivery can be accomplished by parenteral injection (e.g., subcutaneously, intraperitoneally, intradermal, intravenously, intramuscularly, or to the interstitial space of a tissue), or mucosally, such as by rectal, oral (e.g., tablet, spray), vaginal, topical, transdermal (See e.g., WO99/27961) or transcutaneous (See e.g., WO02/074244 and WO02/064162), inhalation, intranasal (See e.g., WO03/028760), ocular, aural, pulmonary or other mucosal administration.
- parenteral injection e.g., subcutaneously, intraperitoneally, intradermal, intravenously, intramuscularly, or to the interstitial space of a tissue
- mucosally such as by rectal, oral (e.g., tablet, spray),
- compositions can also be administered topically by direct transfer to the surface of the skin. Topical administration can be accomplished without utilizing any devices, or by contacting naked skin with the composition utilizing a bandage or a bandage-like device (see, e.g., U.S. Pat. No. 6,348,450).
- the mode of administration is parenteral, mucosal, or a combination of mucosal and parenteral immunizations. In other aspects, the mode of administration is parenteral, mucosal, or a combination of mucosal and parenteral immunizations in a total of 1-2 vaccinations 1-3 weeks apart. In related aspects, the route of administration includes but is not limited to intranasal delivery.
- the invention can include administration of a mutated Bordetella strain to a mammal to elicit an immune response (e.g., a TH1 immune response) capable of impacting an influenza virus, e.g., H3N2.
- an immune response e.g., a TH1 immune response
- mutated Bordetella strains of the invention are described above.
- administration of the mutated Bordetella strain is used to treat or prevent an influenza virus infection in a mammal, e.g., a human, via protective immunity against the influenza virus.
- the mutated Bordetella strain administration is used to prevent influenza infection by administration prior to the influenza virus infection.
- the mutated Bordetella stain is administered to a mammal about less than 1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks prior to the influenza virus infection.
- the method for treating or preventing an infection by an influenza virus includes administering to a subject in need thereof a single dose of a composition of the invention, e.g., BPZE1.
- the administering step is performed mucosally, e.g., intranasally.
- composition of the invention is administered in more than one dose, e.g., two doses.
- the number of doses can vary as needed, for example the number of doses administered to a mammal can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses.
- the method for treating or preventing an infection by an influenza virus includes administering to a subject in need thereof a first immunogenic composition of the invention (comprising e.g., BPZE1) followed by a second immunogenic composition administration (comprising e.g., BPZE1).
- the time range between each dose of the composition can be about 1-6 days, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, or more weeks. In related aspects, the time range between each dose is about 3 weeks.
- prime-boost-style methods can be employed where a composition of the invention can be delivered in a “priming” step and, subsequently, a composition of the invention is delivered in a “boosting” step.
- the composition can typically be used to elicit systemic and/or mucosal immunity, for example to elicit an enhanced systemic and/or mucosal immunity.
- the immune response can be characterized by the induction of a serum IgG and/or intestinal IgA immune response.
- the level of protection against influenza infection can be more than 50%, e.g., 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more.
- the level of protection can be 100%.
- the level of protection is less than 50%, e.g., 20%.
- the number of bacteria in each dosage is adjusted to attain an effective immune response in a mammal.
- the number of bacteria or cfus in each dosage can be about 1, 10, 100, 1000, 10000, 100000, 1000000, 5 ⁇ 10 6 , or more or any dosage between said each dosage.
- the invention can also include co-administration of the composition with another agent or agents.
- the various compositions/agents can be delivered in any order.
- the mutated Bordetella strain need not be all delivered before the agent, e.g., a drug, a siRNA, a miRNA, an immunogenic peptide, or a small molecule capable of effecting an influenza infection.
- agents include neuraminidase inhibitors and M2 inhibitors (adamantanes).
- the priming step can include delivery of one or more agents and the boosting can include delivery of one or more mutated Bordetella strains.
- multiple administrations of mutated Bordetella strains can be followed by multiple administrations of agents. Administrations can be performed in any order.
- one or more of the mutated Bordetella strains described herein and one or more agents can be co-administered in any order and via any administration route known in the art, e.g., to elicit an immune reaction.
- dosage treatment can be according to a single dose schedule or a multiple dose schedule.
- multiple doses can be used in a primary immunization schedule and/or in a booster immunization schedule.
- the various doses can be given by the same or different routes, e.g., a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, and the like.
- the dosage regime can enhance the avidity of the antibody response leading to antibodies with a neutralizing characteristic.
- An in-vitro neutralization assay can be used to test for neutralizing antibodies (see for example Asanaka et al, J Virology 102: 10327, 2005; Wobus et al., PLOS Biology 2; e432; and Dubekti et al., J Medical Virology 66: 400).
- One way of assessing efficacy of therapeutic treatment involves monitoring infection after administration of a composition of the invention.
- One way of assessing efficacy of prophylactic treatment involves monitoring immune responses against the antigens in the compositions of the invention after administration of the composition.
- Another way of assessing the immunogenicity of the compositions of the invention is to isolate the proteins or proteins mixes and to screen patient sera or mucosal secretions by immunoblot. A positive reaction between the protein and the patient serum indicates that the patient has previously mounted an immune response to the composition.
- Another way of checking efficacy of therapeutic treatment involves monitoring infection after administration of the compositions of the invention.
- One way of checking efficacy of prophylactic treatment involves monitoring immune responses both systemically (such as monitoring the level of IgG1 and IgG2a production) and mucosally (such as monitoring the level of IgA production) against the antigens in the compositions of the invention after administration of the composition.
- serum specific antibody responses are determined post-immunization but pre-challenge whereas mucosal specific antibody responses are determined post-immunization and post-challenge.
- the immunogenic compositions of the invention can be evaluated in in vitro and in vivo animal models prior to host, e.g., human, administration.
- compositions of the invention can also be determined in vivo by challenging animal models of infection, e.g., mice, with the compositions.
- the compositions can or cannot be derived from the same strains as the challenge strains.
- In vivo efficacy models can include but are not limited to: (i) A murine infection model using human strains; (ii) a murine disease model which is a murine model using a mouse-adapted strain, such as strains which are particularly virulent in mice; and (iii) a primate model using human isolates.
- the immune response induced by the invention can be one or both of a TH1 immune response and a TH2 response.
- the immune response can be an improved or an enhanced or an altered immune response.
- the immune response can be one or both of a systemic and a mucosal immune response.
- the immune response can be an enhanced systemic and/or mucosal response.
- An enhanced systemic and/or mucosal immunity is reflected in an enhanced TH1 and/or TH2 immune response.
- the enhanced immune response can include an increase in the production of IgG1 and/or IgG2a and/or IgA.
- the mucosal immune response can be a TH2 immune response.
- the mucosal immune response can include an increase in the production of IgA.
- activated TH2 cells enhance antibody production and are therefore of value in responding to extracellular infections.
- Activated TH2 cells can typically secrete one or more of IL-4, IL-5, IL-6, and IL-10.
- a TH2 immune response can also result in the production of IgG1, IgE, IgA, and/or memory B cells for future protection.
- a TH2 immune response can include one or more of an increase in one or more of the cytokines associated with a TH2 immune response (such as IL-4, IL-5, IL-6 and IL-10), or an increase in the production of IgG1, IgE, IgA and memory B cells.
- an enhanced TH2 immune response can include an increase in IgG1 production.
- a TH1 immune response can include one or more of an increase in CTLs, an increase in one or more of the cytokines associated with a TH1 immune response (such as IL-2, IFN-gamma, and TNF-alpha), an increase in activated macrophages, an increase in NK activity, or an increase in the production of IgG2a.
- the enhanced TH1 immune response can include an increase in IgG2a production.
- compositions of the invention in particular, an immunogenic composition comprising one or more strains of the invention can be used either alone or in combination with other agents optionally with an immunoregulatory agent capable of eliciting a Th1 and/or Th2 response.
- compositions of the invention can elicit both a cell-mediated immune response as well as a humoral immune response to effectively address an influenza infection.
- This immune response will preferably induce long lasting (e.g., neutralizing) antibodies and a cell-mediated immunity that can quickly respond upon exposure to one or more infectious antigens in the future.
- compositions of the invention are typically for preventing or treating influenza virus strains in mammalian subjects, e.g., humans.
- subjects can include the elderly (e.g., >65 years old), children (e.g., ⁇ 5 years old), hospitalized patients, healthcare workers, armed service and military personnel, food handlers, pregnant women, the chronically ill, and people traveling abroad.
- the compositions are generally suitable for these groups as well as the general population or as otherwise deemed necessary by a physician.
- kits comprising one or more containers of compositions of the invention.
- Compositions can be in liquid form or can be lyophilized.
- Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes.
- Containers can be formed from a variety of materials, including glass or plastic.
- a container can have a sterile access port (for example, the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- the kit can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery device(s).
- a pharmaceutically-acceptable buffer such as phosphate-buffered saline, Ringer's solution, or dextrose solution.
- the kit can further include a third component comprising an adjuvant.
- the kit can also comprise a package insert containing written instructions for methods of inducing immunity, preventing infections, or for treating infections.
- the package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body.
- FDA Food and Drug Administration
- the invention also provides a delivery device pre-filled with the compositions of the invention.
- the pharmaceutical compositions are generally formulated as sterile, substantially isotonic and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.
- GMP Good Manufacturing Practice
- the bacterial strain used in this study is B. pertussis BPZE1, a streptomycin-resistant Tohamal derivative deleted for the dermonecrotic (DNT)-encoding gene, producing inactivated pertussis toxin (PT) and background levels of tracheal cytotoxin (TCT) (22).
- BPZE1 bacteria were grown at 37° C. for 72 h on Bordet-Gengou (BG) agar (Difco, Detroit, Mich.) supplemented with 1% glycerol, 10% defibrinated sheep blood and 100 ⁇ g/ml streptomycin (Sigma Chemical CO., St Louis, Mo.).
- mice Six to eight week-old female Balb/c mice were kept under specific pathogen-free conditions in Individual Ventilated Cages, and all experiments were carried out under the guidelines of the National University of Singapore animal study board.
- BPZE1 treatment sedated mice were intranasally administered once, twice or three times (as indicated) with approximately 5 ⁇ 106 colony-forming units (cfu) of live or dead BPZE1 bacteria in 20 ⁇ l sterile PBS supplemented with 0.05% TWEEN® 80 (Sigma) (PBST) as previously described (Mielcarek N, et al., “Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen”, Infect immune 65: 544-550, 1997).
- mice For influenza infection, sedated mice were nasally administered with approximately 2 ⁇ 10 6 TCID 50 of mouse-adapted A/Aichi/2/68 (H3N2) virus passage 10 (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009) or 4 lethal dose (LD)50 of H1N1 (A/PR/8/34) influenza virus (ATCC #VR-95) in 20 ⁇ l sterile PBS supplemented with penicillin and streptomycin. Ten mice per group were used to determine the survival rates based on body weight loss and the mice were euthanized when body weight loss exceeded 20% of the original body weight.
- H3N2 mouse-adapted A/Aichi/2/68 virus passage 10
- LD lethal dose
- H1N1 A/PR/8/34 influenza virus
- TCID 50 tissue culture infectious dose 50
- mice per group Four mice per group were sacrificed and their lungs were harvested 3 days post-viral challenge. The lungs were removed and fixed in 10% formalin in PBS. After fixation, the lungs were embedded in paraffin, sectioned, and stained with H&E.
- BALFs Bronchoalveolar Lavage Fluids
- BALFs were recovered by injecting 1 ml of sterile PBS into the lungs of sacrificed animals and performing one lavage step ensuring that both lungs inflated during the process. BALFs were then centrifuged at 400 g for 10 min, and the supernatant was removed and stored at ⁇ 80° C. for cytokine detection. Total BALF cell number was determined using a hemocytometer.
- the cells were spotted onto a glass slide using a Cytospin device (Thermo Shandon), and were stained with a modified Wright staining procedure (Kimman T G, et al., “Development and antigen specificity of the lymphoproliferation response of pigs to pseudorabies virus: dichotomy between secondary B- and T-cell responses”, Immunology 86: 372-378, 1995). Identification of the different cell types was performed using standard morphological criteria. Results are expressed as the percentage of each cell type in the total cell population. A total of 500 cells were considered per slide. Four mice per group were individually assessed.
- mice were sacrificed, their lungs were harvested and single cell suspensions were prepared by digesting the lungs at 37° C. for 15 min in 2 ml digestion buffer containing 0.5 mg/ml Liberase (Roche) in RPMI with 1% FCS and 2 U/ml DNaseI (Qiagen), followed by centrifugation on Ficoll-PaqueTMPLUS (GE) for 20 min at 600 g and room temperature. Cells were collected and washed twice with sterile FACS buffer (2% FCS, 5 mM EDTA in PBS). 10 6 cells were stained with FITC-labeled anti-mouse CD3 antibody (eBioscience) and analyzed on CyAnTM ADP cytometer (Dako). Five mice per group per time point were individually assessed.
- 2 ml digestion buffer containing 0.5 mg/ml Liberase (Roche) in RPMI with 1% FCS and 2 U/ml DNaseI (Qiagen), followed by centrifugation on Ficoll
- Cytokine and chemokine production in the BALFs supernatants was measured using Procarta cytokine profiling kit, according to the manufacturer's instructions (Panomics). After incubation with Ab-conjugated beads, detection Abs and streptavidin-PE complexes, samples were run on Bio-Plex instrument (Bio-Rad). Levels of the following growth factors, cytokines, and inflammatory mediators were evaluated: GM-CSF, KC, IL-1 ⁇ , IL-6, IFN- ⁇ and TNF- ⁇ , IFN- ⁇ , MCP-1 RANTES, IL-10. In addition, TGF- ⁇ levels were measured using a Human/Mouse TGF ⁇ 1 ELISA kit (eBioscience) according to the manufacturer's instructions.
- a high titer anti- B. pertussis immune serum was generated in 10 adult Balb/c mice nasally infected twice at a 4-week interval with 5 ⁇ 10 6 cfu of live BPZE1 bacteria.
- Another group of 10 adult na ⁇ ve Balb/c mice were injected intraperitoneally (ip.) with 10 5.5 TCID 50 of heat-inactivated human/Aichi/2/68 (H3N2) virus (HI-H3N2) in complete Freund's adjuvant and boosted with the same amount of HI-H3N2 virus in incomplete Freund's adjuvant 2 weeks later.
- H3N2 heat-inactivated human/Aichi/2/68
- mice The immune sera from each mouse group were collected 2 weeks after the boost, pooled and the anti-pertussis and anti-influenza antibody titers were measured by ELISA. Moreover, HI-H3N2 serum was tested for the presence of neutralizing antibodies by neutralization assay. The immune sera were filter-sterilized, heat inactivated at 56° C. for 30 min and stored at ⁇ 80° C. until further use. Sera from control na ⁇ ve mice were also collected as negative control.
- mice Six to eight week-old recipient Balb/c mice were ip. injected with 200 ⁇ l of na ⁇ ve, anti-BPZE1 or anti-H3N2 immune serum 1 day prior viral challenge with mouse-adapted H3N2 virus. Body weight losses were monitored to determine the survival rates. Ten mice per group were assayed.
- Lymphocyte proliferation was measured by incorporation of tritiated (3H) thymidine as described elsewhere (Bao Z, et al., “Glycogen synthase kinase-3beta inhibition attenuates asthma in mice”, Am J Respir Crit Care Med 176: 431-438, 2007). Briefly, spleens from na ⁇ ve and BPZE1-treated mice (6 mice per group) were collected under aseptic condition and pooled. Single-cell suspensions were prepared and centrifuged on Ficoll-PaqueTMPLUS (GE) for 20 min at 600 g at room temperature.
- Ficoll-PaqueTMPLUS GE
- the isolated splenocytes were seeded in 96-well round-bottom plates (NUNC) at a density of 2 ⁇ 10 5 cells/well in 100 ⁇ l medium (RPMI640 supplemented with 10% FCS, 5 ⁇ 10-5 M ⁇ -mercaptoethanol, 2 mM L-glutamine, 10 mM HEPES, 200 U/ml penicillin, 200 ⁇ g/ml streptomycin).
- 100 ⁇ l medium containing 20 ⁇ g/ml of BPZE1 whole cell lysate or heat-inactivated 10 5 TCID 50 mouse-adapted H3N2 influenza virus (HI-H3N2) (test antigen) were added to the splenocytes.
- Results are expressed as stimulation index (SI) corresponding to the ratio between the mean of [ 3 H]thymidine uptake in the presence of test antigen and the mean of [ 3 H]thymidine uptake in the absence of test antigen. A SI>2 was considered positive. Each sample was assayed in quadruplicate.
- the frequency of antigen-specific IFN- ⁇ -producing splenocytes was determined by ELISPOT assay using BD mouse ELISPOT set (BD PharMingen) according to the manufacturer's instructions. Briefly, single-cell suspensions of individual spleen from na ⁇ ve and BPZE1-treated mice were prepared and plated in 96-well microplates (Millipore, Bedford, MA) pre-coated with 100 ⁇ l of [5 ⁇ g/ml anti-IFN- ⁇ antibody in sterile PBS] overnight at 4° C., washed three times and blocked for 2 hr at room temperature with RPMI 1640 containing 10% FCS.
- BD PharMingen BD mouse ELISPOT set
- bars represent means ⁇ SD and averages were compared using a bidirectional unpaired Student's t test with a 5% significance level with * p ⁇ 0.05, **p ⁇ 0.01 and ***p ⁇ 0.001.
- Example 1 A Single Nasal Administration of Live Attenuated Bordetella Pertussis Protects Against H 3N2 Influenza Challenge
- H3N2 influenza virus was obtained through successive lung-to-lung passages of the A/Aichi/2/68 (H3N2) virus into adult Balb/c mice (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009).
- Passage 10 (P10) strain exhibited high virulence, causing extra-pulmonary spread with necrotic and inflammatory lesions in the various organs of the infected animals
- Nasal administration of 2 ⁇ 10 6 TCID 50 of the P10 viral suspension caused the death of the animals within 4 days (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009).
- mice were nasally inoculated with live BPZE1 bacteria and subsequently challenged either 3 or 6 weeks later with a lethal dose of mouse-adapted H3N2 virus. Survival rate based on body weight changes indicated that the mice challenged 3 weeks after nasal BPZE1 treatment were not significantly protected whereas 60% protection was achieved when mice were challenged 6 weeks post-BPZE1 treatment ( FIG. 1 ).
- Example 2 Live but not Dead Bpze1 Bacteria Protect Against Lethal H3N2 Challenge
- mice were nasally administered once with live or dead BPZE1 bacteria and were subsequently challenged with a lethal dose of mouse-adapted H3N2 virus 6 weeks post-BPZE1 treatment.
- the results showed that dead bacteria did not provide any significant protection against H3N2 ( FIG. 2 ), suggesting that bacterial colonization of the mouse lung is necessary to induce the protective mechanisms.
- Live BPZE1 bacteria were nasally administered to Balb/c mice twice at a 4-week interval prior lethal challenge with mouse-adapted H3N2 virus performed 4 weeks after the last BPZE1 administration. A 100% protection rate was obtained for the BPZE1-treated animals with minimal body weight changes ( FIG. 3 ). Similar protection rate was achieved when the viral challenge was performed 2 weeks after the boost. These data indicated that a second nasal administration of live BPZE1 bacteria not only enhanced the protection efficacy but also shortened the time necessary to trigger the protective mechanisms.
- Example 4 Bpze1 Bacteria Provide Protection against H1N1 Virus Challenge
- BPZE1 bacteria The protective potential of BPZE1 bacteria against influenza A viruses was further explored. Mice nasally treated once with live BPZE1 bacteria were not protected against a lethal challenge with human A/PR/8/34 (H1N1) influenza A virus performed 6 weeks later (data not shown). However, three consecutive administrations of live BPZE1 bacteria conferred 50% protection against H1N1 virus ( FIG. 4 ). These observations indicated that BPZE1 bacteria can have the potential to protect against all influenza A viruses although with a variable efficacy.
- the viral load was quantified in the lungs of mice treated twice with BPZE1 bacteria and in control mice.
- the virus load was checked 3 days post-infection which corresponds to the peak of virus titer in mice infected with mouse-adapted H3N2 virus (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009).
- No significant difference in the viral load was observed between the two animal groups ( FIG. 5 ). This result suggested that the cross-protective mechanisms triggered in the BPZE1-treated animals do not directly target the virus particles and/or infected cells.
- Example 6 Bpze1 Treatment Protects Mice from Influenza-Induced Immunopathology and Lymphocyte Depletion
- BALFs broncho-alveolar lavage fluids
- mice were treated twice with BPZE1 bacteria and challenged with mouse-adapted H3N2 virus 4 weeks later.
- the mouse lungs were harvested 3 and 5 days post-influenza challenge for FACS analysis of the T cell population.
- the percentage of CD3 + T lymphocytes in the infected control mice and BPZE1-treated mice was comparable to the percentage found in the animals before challenge ( FIG. 6 C ).
- a significant CD3 + T cell depletion was observed in the infected control animals 5 days post-viral challenge ( FIG.
- pro-inflammatory cytokines and chemokines were measured in the BALFs recovered from protected BPZE1-treated mice and compared to non-protected mice, 1 and 3 days after lethal H3N2 virus challenge. All the pro-inflammatory cytokines and chemokines measured in the BALFs of the protected animal group were significantly lower than those measured in the non-protected mice ( FIG. 7 ).
- IL-1 ⁇ , IL-6, IFN- ⁇ and TNF- ⁇ are the main pro-inflammatory cytokines contributing to influenza-induced immunopathology and correlating with disease severity
- IL-1 ⁇ , IL-6, IFN- ⁇ and TNF- ⁇ are the main pro-inflammatory cytokines contributing to influenza-induced immunopathology and correlating with disease severity
- IFN- ⁇ The levels of IFN- ⁇ , MCP-1 and RANTES were found significantly reduced 1 day post-viral challenge whereas the production of IL-12(p70), GM-CSF and KC was lower at day 3 post-challenge. Strikingly, complete suppression of IL-12 production was found in the protected animal group, consistent with lower levels of IFN- ⁇ .
- Example 8 B. Pertussis -Specific Adaptive Immunity is not Involved in the Cross-Protection
- CCR2 primary receptor for MCP-1-deficient mice displayed reduced mortality but a significantly elevated viral burden associated with decreased pulmonary cell infiltration and tissue damage (Dawson T C, et al., “Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus”, Am J Pathol 156: 1951-1959, 2000).
- IL-1R knock-out mice showed increased mortality associated with delayed viral clearance but less severe pathology (Schmitz N, et al., “Interleukin-1 is responsible for acute lung immunopatholoy but increases survival of respiratory influenza virus infection”, J Virol 79: 6441-6448, 2005).
- Cytokine storm characterized by excessive levels of chemokines and cytokines in the serum and lungs due to uncontrolled activation of the host's immune system, was indeed correlated with the fatal outcome of experimental animals infected with reconstructed 1918 H1N1 and H5N1 influenza viruses (Kash J C, et al., “Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus”, Nature 443: 578-581, 2006; Simon A K, et al., “Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes”, Proc Natl Acad Sci USA 98: 5158-5163, 2001; Kobasa D, et al., “Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus”, Nature 445: 319-323, 2007; Tumpey T M, et al., “Characterization of the reconstructed 1918 Spanish influenza pande
- histological and pathological indicators strongly suggest a key role for an excessive host response in mediating at least some of the extreme pathology associated with highly pathogenic influenza viruses.
- the role of each individual cytokine during influenza infection has remained unclear with often both positive and negative effects; Although their production can be important for viral clearance through the recruitment and/or activation of immune effector cells on the site of infection, their inflammatory properties can also lead to tissue damage (La Gruta N L, et al., “A question of self-preservation immunopathology in influenza virus infection”, Immunol Cell Biol 85: 85-92 2007).
- IL-12 measured in the protected animals likely impaired the activation of some immune cells such as natural killer (NK) cells and cytotoxic CD8 + T cells. Both cell types have been described potentially harmful and involved in immunopathology upon release of inflammatory mediators (La Gruta N L, et al., “A question of self-preservation: immunopathology in influenza virus infection”, Immunol Cell Biol 85: 85-92 2007). Consistently, IFN- ⁇ production, a hallmark for NK and CD8 + T cell activation, was found significantly lower in the BALFs recovered from the protected animals.
- the lower IFN- ⁇ production can affect the neutrophil responses to the virus, including oxidative burst, induction of antigen presentation and chemokine production (Ellis T N and Beaman B L, “Interferon-gamma activation of polymorphonuclear neutrophil function”, Immunology 112: 2-11, 2004; Farrar M A and Schreiber R D, “The molecular cell biology of interferon-gamma and its receptor”, Annu Rev Immunol 11: 571, 1993).
- lymphocyte apoptosis can thus not be a direct cytolytic effect of the virus itself. Instead, our data are consistent with previous studies which suggested that in H5N1-infected humans and mice, lymphocyte apoptosis was likely caused by cytokine dysregulation and overactivation of the host immune response (Uiprasertkul M, et al., “Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans”, Emerg Infect Dis 13: 708-712, 2007; Maines T R, et al., “Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response”, Immunol Rev 225: 68-84, 2008).
- TNF- ⁇ and related TNF-superfamily members including TNF-related apoptosis inducing ligand are known to induce T cell apoptosis (Simon A K, et al., “Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes”, Proc Natl Acad Sci USA 98: 5158-5163, 2001; Wang J, et al., “The critical role of LIGHT, a TNF family member, in T cell development”, J Immunol 167: 5099-5105, 2001). Consistently, lower levels of TNF- ⁇ were measured in the BALFs of protected BPZE1-treated mice upon influenza challenge, thus potentially translating into lower T cell apoptosis.
- TRAIL TNF-related apoptosis inducing ligand
- B. pertussis virulence factors Much of the activity of B. pertussis virulence factors is dedicated to immunomodulation so as to suppress, subvert and evade the host defense system (Carbonetti N H, “Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease”, Curr Opin Pharmacol 7: 1-7, 2007). The immune response to B.
- TLR toll-like receptor
- DCs dendritic cells
- FHA Filamentous hemagglutinin
- BPZE1-treated mice displayed minimal lung immunopathology, consistent with reduced neutrophil infiltration and lower production of a variety of major pro-inflammatory cytokines and chemokines in their BALFs.
- Our findings thus strongly suggest that protection against influenza A viruses induced-lethal pneumonitis can be achieved through attenuation of inflammation and dampening of the cytokine storm, and demonstrate the potential use of BPZE1 bacteria as an effective prophylactic means of protecting against virulent influenza A virus infections.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
Description
- The present application is a continuation application of U.S. patent application Ser. No. 15/353,758 filed on Nov. 17, 2016, which is a continuation application of U.S. patent application Ser. No. 13/377,070 filed on Feb. 2, 2012 (now U.S. Pat. No. 9,526,778) which is a national stage entry application under 35 U.S.C. 371 of international patent application number PCT/IB09/07153 filed on Jun. 15, 2009, which designated the U.S.
- The invention relates to fields of microbiology and virology.
- There are three types of influenza virus: A, B, and C, which vary greatly in their epidemiological pattern. Influenza A virus is both the best characterized and the most serious threat to public health, capable of inducing massive epidemics or pandemics. This virus is also highly variable antigenically, making effective vaccine production difficult.
- A vaccine to influenza would be one of the most efficacious, safe, nontoxic, and economical weapons to prevent disease and to control the spread of the disease. The primary aim of vaccination is to activate the adaptive specific immune response, primarily to generate B and T lymphocytes against antigen(s) associated with the disease or the disease agent.
- Currently some vaccines against influenza are available and primarily consist of inactivated vaccines. These vaccines can comprise two type A antigens (e.g., H1N1 and H3N2) and one type B antigen. The available vaccines typically include whole virion, split-product, and subunit vaccines. Generally, these vaccines are effective in up to 90% of vaccinated individuals if the vaccines closely match the identity of the emerging epidemic. However, they need to be updated each year to keep pace with antigenic drift of the influenza virus.
- Moreover, a cold-adapted live attenuated intranasal vaccine (LAIV) against seasonal influenza has been recently described. Cross-protective immunity was demonstrated in a study which reported protection against a H3N2 virus in cotton rats infected with a H1N1 strain. However, one major concern linked with LAIV is the possibility of genetic reversion and re-assortment with wild-type influenza viruses, resulting in a new, potentially infectious strain.
- The invention addresses these and other problems in the influenza vaccine field by providing a vaccine and composition that elicits an immune response against one or more influenza strains using a mutated Bordetella strain as the active principle agent.
- In addition, the related art describes various types of vaccines and compositions using Bordetella strains (WO2007104451 and WO2003102170) to induce immune responses against, e.g., Bordetella bacteria capable of causing whooping cough in humans; however the art fails to disclose methods or compositions for eliciting an immune response to an influenza virus in a mammal using the methods, compositions, and/or vaccines of the invention.
- Thus, a need exists for a novel influenza vaccine capable of providing broad protection against diseases caused by influenza virus infection.
- The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
- In one aspect, the invention provides a method of eliciting an immune response against an influenza virus in a mammal, comprising: administering a mutated Bordetella strain to the mammal, wherein the strain comprises a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene. In some aspects, the Bordetella strain comprises a Bordetella pertussis strain. In some such aspects, the wild-type Bordetella strain ampG gene is replaced by an E. coli ampG gene. In other aspects, the mutation of the ptx gene comprises the substitution of an amino acid involved in substrate binding and/or an amino acid involved in catalysis. In some such aspects, the substitution of the amino acid involved in substrate binding comprises R9K and the substitution of the amino acid involved in catalysis comprises E129G. In some aspects, the Bordetella strain comprises a triple mutant strain. In some such aspects, the Bordetella strain comprises a BPZE1 strain. In other such aspects, the Bordetella strain is attenuated. In some aspects, the Bordetella strain comprises a live strain. In other aspects, the Bordetella strain does not comprise a heterologous gene other than the heterologous ampG gene. In some aspects, the Bordetella strain does not comprise a heterologous expression platform to carry heterologous antigens to the respiratory mucosa of the mammal. In other aspects, the methods further comprise the prevention or treatment of the influenza infection in the mammal. In some aspects, the Bordetella strain is administered prior to the influenza infection. In some such aspects, the Bordetella strain is administered about 6 weeks or more prior to the influenza infection. In other such aspects, the Bordetella strain is administered about 12 weeks or more prior to the influenza infection. In some aspects, the influenza virus comprises H3 or H1. In other aspects, the influenza virus comprises N2 or N1.
- In some aspects, the influenza virus comprises H3 and N2. In other aspects, the influenza virus comprises H1 and N1. In some aspects, the immune response comprises a Th1 immune response. In some aspects, the strain is administered to the mammal by subcutaneous (s.c.), intradermal (i.d.), intramuscular (i.m.), intravenous (i.v.), oral, or intranasal administration; or by injection or by inhalation. In other aspects, the strain is administered intranasally. In some other aspects, the strain is administrated to a mammal in need of protective immunity against the influenza infection. In some aspects the mammal is a child. In some aspects, the strain is administered once in a single dose. In some aspects, the strain is administered in more than one dose. In some such aspects, the strain is administered twice in two doses. In other aspects, the two doses are administered about 3 weeks apart. In some aspects, a level of protection against the influenza infection is more than about 60%. In other aspects, a level of protection against the influenza infection is more than about 50%. In some aspects, the mammal is a human.
- In another aspect, the invention provides methods of eliciting a protective immune response against an H3N2 influenza virus in a human, comprising: intranasally administering a live and attenuated BPZE1 strain to the human prior to infection of the human by the H3N2 influenza virus, wherein the strain does not comprise a heterologous expression platform to carry heterologous antigens to the respiratory mucosa of the human.
- In another aspect, the invention provides methods of eliciting an immune response against an influenza virus in a human, comprising: administering a live Bordetella strain to the human, wherein the strain does not comprise a heterologous expression platform to carry heterologous antigens to the respiratory mucosa of the human.
- In another aspect, the invention provides methods of protecting a mammal against a disease caused by an influenza infection, comprising: administering to the mammal a mutated Bordetella strain comprising a mutated ptx gene, a deleted or mutated dnt gene, and a heterologous ampG gene.
- In another aspect, the invention provides a protective immunity against an influenza infection, comprising: administering to the mammal a mutated Bordetella strain comprising a mutated ptx gene, a deleted or mutated dnt gene, and a heterologous ampG gene.
- In another aspect, the invention provides a composition for treating or preventing an influenza infection in a mammal, comprising: a mutated Bordetella strain, wherein the strain comprises a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene. In some aspects, the Bordetella strain comprises a Bordetella pertussis strain. In other aspects, the wild-type Bordetella strain ampG gene is replaced by an E. coli ampG gene. In some aspects, the mutation of the ptx gene comprises the substitution of an amino acid involved in substrate binding and/or an amino acid involved in catalysis. In other aspects, the substitution of the amino acid involved in substrate binding comprises R9K and the substitution of the amino acid involved in catalysis comprises E129G. In some aspects, the Bordetella strain comprises a triple mutant strain.
- In another aspect, the invention provides a vaccine comprising a composition of the invention for treating or preventing the influenza infection in the mammal. In some aspects, the vaccine comprises a Bordetella strain composition described herein. In some aspects, the vaccine is formulated for intranasal administration.
- In another aspect, the invention provides a Bordetella strain identified by accession number CNCM 1-3585.
- In another aspect, the invention provides a Bordetella strain identified by accession number V09/009169.
- These and other features, aspects, and advantages of the invention will become better understood with regard to the following description, and accompanying drawings, where:
-
FIGS. 1A and 1B show protection rate of BPZE1-treated mice against lethal challenge with mouse-adapted H3N2 virus. Adult Balb/c mice were nasally administered with 5×106 cfu of BPZE1 bacteria and challenged either 3 weeks (solid square) or 6 weeks (solid triangle) later with a lethal dose (2LD50) of mouse-adapted H3N2 virus. Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid lozenge). 10 animals per group were assessed. Results are representative of three independent experiments. -
FIG. 2 shows protection rates against lethal challenge with mouse-adapted H3N2 virus in mice treated with dead versus live BPZE1 bacteria. Adult Balb/c mice were nasally administered with 5×106 cfu of live (solid triangle) or dead (solid square) BPZE1 bacteria, and challenged 6 weeks later with a lethal dose (2LD50) of mouse-adapted H3N2 virus. Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid lozenge). 10 animals per group were assessed. Results are representative of two independent experiments. -
FIGS. 3A and 3B show protection rate against lethal challenge with mouse-adapted H3N2 virus in mice treated twice with live BPZE1 bacteria. Adult Balb/c mice were nasally administered twice at a 4-week interval with 5×106 cfu of BPZE1 bacteria (solid square) and challenged 4 weeks later with a lethal dose (2LD50) of mouse-adapted H3N2 virus. Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid lozenge). 10 animals per group were assessed. Results are representative of two independent experiments. -
FIGS. 4A and 4B show protection rate of BPZE1-treated mice against lethal challenge with H1N1 influenza A virus. Adult Balb/c mice were nasally administered three times at 4-week and 3-week intervals (solid triangle) with 5×106 cfu of live BPZE1 bacteria. The animals were challenged with a lethal dose (4 LD50) of A/PR/8/34 (H1N1)influenza A virus 2 weeks after the last BPZE1 treatment. Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid lozenge). 10 animals per group were assessed. Results are representative of 2 independent experiments. -
FIG. 5 shows viral load quantification in the lungs of protected versus non-protected mice. Adult Balb/c mice were nasally administered twice at a 4-week interval with 5×106 cfu of live BPZE1 bacteria and challenged 4 weeks later with a lethal dose (2LD50) of mouse-adapted H3N2 virus. Five animals per group were sacrificed 3 days post-viral challenge, their lungs were harvested and individually processed for in vitro determination of TCID50 upon infection of MDCK cells. The viral load was compared with that obtained in non-treated mice. Results are representative of 3 independent experiments. -
FIGS. 6A and 6B show lung histology and cellular infiltrates and CD3+ T cell population in the lungs in BPZE1-treated versus non-treated mice after lethal viral challenge. Adult Balb/c mice were nasally administered with 5×106 cfu of live BPZE1 bacteria and challenged 6 weeks later with a lethal dose (2LD50) of mouse-adapted H3N2 virus. Three days post-viral challenge, mice were euthanized and their lungs were individually processed for histology analysis (A) or broncho-alveolar lavages for analysis of the cellular infiltrates (B). Legend A: Infected control mice displayed severe inflammation, pulmonary edema (black arrow) and severe necrotizing bronchitis with necrotic cell debris (open arrow). Infected BPZE1-treated mice showed only minimal inflammation and airway damage, and mild peribronchular damage. Representative fields are shown. Results were equivalent in more than 40 fields analyzed per group (>5 fields/section, 2 sections/mouse and 4 mice/group). Legend B: a, naïve mice non-challenged; b, naïve mice challenged with H3N2 virus; c, BPZE1-treated mice non-challenged; d, BPZE1-treated mice challenged with H3N2 virus. Four animals per time point per group were individually assessed. **, p≤0.01; ***, p≤0.001. Results are representative of two independent experiments. (C). FACS analysis of the CD3+ T cell population in the mice lungs. 3 days or 5 days after lethal H3N2 influenza virus challenge, non-treated control mice and mice treated twice with BPZE1 were euthanized and CD3+ T cell population in their lungs were analyzed by flow cytometry. Four animals per time point per group were individually assessed. Results are expressed in percentage of CD3+ T cells in the total lung cell population. mean±SD. Legend: a, naïve mice non-challenged; b, BPZE1-treated mice non-challenged; c, naïve mice challenged with H3N2 virus and sacrificed 3 days later; d, BPZE1-treated mice challenged with H3N2 virus and sacrificed 3 days later; e, naïve mice challenged with H3N2 virus and sacrificed 5 days later; f, BPZE1-treated mice challenged with H3N2 virus and sacrificed 5 days later. ***, p≤0.001. -
FIGS. 7A-7L show pro- and anti-inflammatory cytokine and chemokine profiles in the BPZE1-treated versus non-treated mice after lethal H3N2 viral challenge. Adult Balb/c mice were nasally administered twice at a 4-week interval with 5×106 cfu of live BPZE1 bacteria and were challenged with a lethal dose (2LD50) of mouse-adaptedH3N2 virus 4 weeks after the last administration. One and three days post-viral challenge, five mice per group and per time point were sacrificed and broncho-alveolar lavages fuilds (BALFs) were collected. 14 inflammation-related cytokines and chemokines were measured in each individual BALF sample. Legend: 1, non-treated non-challenged mice; 2, BPZE1-treated non-challenged mice; 3, non-treated challenged mice and sacrificed 1 day post-challenge; 4, BPZE1-treated challenged mice and sacrificed 1 day post-challenge; 5, non-treated challenged mice and sacrificed 3 days post-challenge; 6, BPZE1-treated challenged mice and sacrificed 3 days post-challenge. *, p<0.05; **, p≤00.01; ***, p≤00.001. -
FIGS. 8A-8C show role of the B. pertussis-specific immunity in the cross-protection. (A). Naive (open triangle) or anti-H3N2 (solid circle) or anti-BPZE1 (open circle) immune serum was ip. injected to adult naïve Balb/c mice one day prior to lethal challenge (2LD50) with mouse-adapted H3N2 virus. Body weight changes were monitored daily and mice were euthanized when body weight loss exceeded 20% of the original body weight. Survival rates were compared to non-treated mice (solid triangle). 10 animals per group were assessed. (B) & (C). Adult Balb/c mice were nasally administered with 5×106 cfu of live BPZE1 bacteria and 6 weeks later the animals were euthanized and their spleens were harvested. Pooled (B) or individual (C) splenocytes from 6 animals were stimulated with either BPZE1 lysate or heat-inactivated H3N2 virus particles. 3H-thymidine incorporation (B) and IFN-γ ELISPOT assay (C) were performed as described below. Representative of two different experiments, both showed similar results; mean±SD; *, p<0.05, ***, p<0.001. - The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
- Terms used in the claims and specification are defined as set forth below unless otherwise specified.
- As used herein, the abbreviation “PTX” refers to pertussis toxin, which synthesizes and secretes an ADP-ribosylating toxin. PTX is comprised of five different subunits (named S1-S5) with each complex containing two copies of S4. The subunits are arranged in an A-B structure. The A component is enzymatically active and is formed from the S1 subunit, while the B component is the receptor binding portion and is made up of subunits S2-S5.
- As used herein the abbreviation “DNT” refers to pertussis dermonecrotic toxin, which is a heat labile toxin that can induce localized lesions in mice and other laboratory animals when it is injected intradermally.
- As used herein the abbreviation “TCT” refers to tracheal cytotoxin, which is a virulence factor synthesized by Bordetellae. TCT is a peptidoglycan fragment and has the ability to induce interleukin-1 production and nitric oxide synthase. It has the ability to cause stasis of cilia and has lethal effects on respiratory epithelial cells.
- The term “attenuated” refers to a weakened, less virulent Bordetella strain that is capable of stimulating an immune response and creating protective immunity, but does not generally cause illness.
- The term “rapid protective immunity” means that immunity against Bordetella is conferred in a short time after administration of the mutated Bordetella strain of the invention.
- The term “Bordetella strain” or “strain” includes strains from Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica.
- The term “child” is meant to be a person or a mammal between 0 months and 18 years of age.
- “Treating” refers to any indicia of success in the treatment or amelioration or prevention of the disease, condition, or disorder, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the disease condition more tolerable to the patient; slowing in the rate of degeneration or decline; or making the final point of degeneration less debilitating. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of an examination by a physician. Accordingly, the term “treating” includes the administration of the compounds or agents of the invention to prevent or delay, to alleviate, or to arrest or inhibit development of the symptoms or conditions associated with a disease, condition or disorder as described herein. The term “therapeutic effect” refers to the reduction, elimination, or prevention of the disease, symptoms of the disease, or side effects of the disease in the subject. “Treating” or “treatment” using the methods of the invention includes preventing the onset of symptoms in a subject that can be at increased risk of a disease or disorder associated with a disease, condition or disorder as described herein, but does not yet experience or exhibit symptoms, inhibiting the symptoms of a disease or disorder (slowing or arresting its development), providing relief from the symptoms or side effects of a disease (including palliative treatment), and relieving the symptoms of a disease (causing regression). Treatment can be prophylactic (to prevent or delay the onset of the disease, or to prevent the manifestation of clinical or subclinical symptoms thereof) or therapeutic suppression or alleviation of symptoms after the manifestation of the disease or condition.
- “Concomitant administration” of a known drug (or other compound) with the composition of the invention means administration of the drug (or other compound) together with the composition at such time that both the known drug (or other compound) will have a therapeutic effect or diagnostic effect. Such concomitant administration can involve concurrent (i.e., at the same time), prior, or subsequent administration of the drug (or other compound) with respect to the administration of a composition of the invention. A person of ordinary skill in the art would have no difficulty determining the appropriate timing, sequence, and dosages of administration for particular drugs (or other compounds) together with compositions of the invention.
- The terms “protection” and “prevention” are used herein interchangeably and mean that an infection by influenza is impeded.
- “Prophylaxis vaccine” means that this vaccine prevents influenza infection upon future exposure.
- The term “immunogenic composition” or “composition” means that the composition can induce an immune response and is therefore antigenic. By “immune response” means any reaction by the immune system. These reactions include the alteration in the activity of an organism's immune system in response to an antigen and can involve, for example, antibody production, induction of cell-mediated immunity, complement activation, or development of immunological tolerance.
- As used herein, the term “disease” has the meaning generally known and understood in the art and comprises any abnormal condition in the function or well being of a host individual. A diagnosis of a particular disease by a healthcare professional can be made by direct examination and/or consideration of results of one or more diagnostic tests.
- The terms “live vaccine composition”, “live vaccine”, “live bacterial vaccine”, and similar terms refer to a composition comprising a strain of live Bordetella bacteria that provides at least partial protective immunity against influenza.
- The terms “oral”, “enteral”, “enterally”, “orally”, “non-parenteral”, “non-parenterally”, and the like, refer to administration of a compound or composition to an individual by a route or mode along the alimentary canal. Examples of “oral” routes of administration of a composition include, without limitation, swallowing liquid or solid forms of a vaccine composition from the mouth, administration of a vaccine composition through a nasojejunal or gastrostomy tube, intraduodenal administration of a vaccine composition, and rectal administration, e.g., using suppositories that release a live bacterial vaccine strain described herein.
- The term “topical administration” refers to the application of a pharmaceutical agent to the external surface of the skin or the mucous membranes (including the surface membranes of the nose, lungs and mouth), such that the agent crosses the external surface of the skin or mucous membrane and enters the underlying tissues. Topical administration can result in a limited distribution of the agent to the skin and surrounding tissues or, when the agent is removed from the treatment area by the bloodstream, systemic distribution of the agent. In a preferred form, the agent is delivered by transdermal delivery, e.g., using a transdermal patch. Transdermal delivery refers to the diffusion of an agent across the skin (stratum corneum and epidermis), which acts as a barrier few agents are able to penetrate. In contrast, the dermis is permeable to absorption of many solutes and drugs, and topical administration therefor occurs more readily through skin which is abraded or otherwise stripped of the epidermis to expose the dermis. Absorption through intact skin can be enhanced by combining the active agent with an oily vehicle (e.g., creams, emollients, penetration enhancers, and the like, as described, e.g., in Remington's Pharmaceutical Sciences, current edition, Gennaro et al., eds.) prior to application to the skin (a process known as inunction).
- The term “nasal administration” refers to any form of administration whereby an active ingredient is propelled or otherwise introduced into the nasal passages of a subject so that it contacts the respiratory epithelium of the nasal cavity, from which it is absorbed into the systemic circulation. Nasal administration can also involve contacting the olfactory epithelium, which is located at the top of the nasal cavity between the central nasal septum and the lateral wall of each main nasal passage. The region of the nasal cavity immediately surrounding the olfactory epithelium is free of airflow. Thus, specialized methods must typically be employed to achieve significant absorption across the olfactory epithelium.
- The term “aerosol” is used in its conventional sense as referring to very fine liquid or solid particles carried by a propellant gas under pressure to a site of therapeutic application. A pharmaceutical aerosol of the invention contains a therapeutically active compound, which can be dissolved, suspended, or emulsified in a mixture of a fluid carrier and a propellant. The aerosol can be in the form of a solution, suspension, emulsion, powder, or semi-solid preparation. Aerosols of the invention are intended for administration as fine, solid particles or as liquid mists via the respiratory tract of a patient. Various types of propellants can be utilized including, but not limited to, hydrocarbons or other suitable gases. Aerosols of the invention can also be delivered with a nebulizer, which generates very fine liquid particles of substantially uniform size within a gas. Preferably, a liquid containing the active compound is dispersed as droplets, which can be carried by a current of air out of the nebulizer and into the respiratory tract of the patient.
- The term “ameliorating” refers to any therapeutically beneficial result in the treatment of a disease state, e.g., an influenza-related disease state, including prophylaxis, lessening in the severity or progression, remission, or cure thereof.
- In general, the phrase “well tolerated” refers to the absence of adverse changes in health status that occur as a result of the treatment and would affect treatment decisions.
- “Synergistic interaction” refers to an interaction in which the combined effect of two or more agents is greater than the algebraic sum of their individual effects.
- The term “in vitro” refers to processes that occur in a living cell growing separate from a living organism, e.g., growing in tissue culture.
- The term “in vivo” refers to processes that occur in a living organism.
- The term “mammal” as used herein includes both humans and non-humans and include but is not limited to humans, non-human primates, canines, felines, murines, bovines, equines, and porcines.
- The term “sufficient amount” means an amount sufficient to produce a desired effect, e.g., an amount sufficient to modulate protein aggregation in a cell.
- The term “therapeutically effective amount” is an amount that is effective to ameliorate a symptom of a disease. A therapeutically effective amount can be a “prophylactically effective amount” as prophylaxis can be considered therapy.
- As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but can include other elements not expressly listed or inherent to such process or method. Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
- It is to be understood that this invention is not limited to particular methods, reagents, compounds, compositions, or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a vaccine” includes a combination of two or more vaccines, and the like.
- “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
- The invention is generally used to treat or prevent influenza virus infection in mammals There are three types of influenza viruses that can be targeted by the invention: Influenza A, B, and C. Influenza type A viruses are divided into subtypes based on two proteins on the surface of the virus. These proteins are termed hemagglutinin (H) and neuraminidase (N). Influenza A viruses are divided into subtypes based on these two proteins. There are 16 different hemagglutinin subtypes H1, H2, H3, H5, H4, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 or H16 and 9 different neuraminidase subtypes N1, N2, N3, N4, N5, N6, N7, N8, or N9, all of which have been found among influenza A viruses in wild birds. Influenza A viruses include A(H1N1) and A(H3N2), both of which are examples of influenza viruses that can be targeted by the invention for treatment or prevention in a mammal Diseases and symptoms typically caused by influenza virus infection can include: fever, coughing, sneezing, aches, fatigue, headache, watery eyes, nasal congestion, and abdominal pain. The invention can be used to treat or prevent these diseases.
- The invention provides a mutated Bordetella strain that can be used as an immunogenic composition or a vaccine to elicit an immune response in a mammal. In one aspect, the mutated Bordetella strain contains a mutated ptx gene, a deleted or mutated dnt gene, and a heterologous ampG gene. The heterologous ampG gene product can reduce in large quantities the amount of tracheal cytotoxin that is produced. In one aspect, the strain is BPZE1. The starting strain which is mutated can be any Bordetella strain including Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica. In one aspect the starting strain used to obtain the mutated Bordetella strain is B. pertussis. In another aspect, the strain is a triple mutant Bordetella strain. In another aspect, the Bordetella strain is identified by accession number CNCM 1-3585. In another aspect, the Bordetella strain is identified by accession number V09/009169.
- The invention is not limited to only the mutants described above. Other additional mutations can be undertaken such as adenylate cyclase (AC) deficient mutants, lipopolysaccharide (LPS) deficient mutants, filamentous hemagglutinin (FHA), and any of the bvg-regulated components.
- The construction of a mutated Bordetella strain of the invention can begin with replacing the Bordetella ampG gene in the strain with a heterologous ampG gene. Any heterologous ampG gene known in the art can be used in the invention. Examples of these can include all gram-negative bacteria that release very small amounts of peptidoglycan fragments into the medium per generation. Examples of gram-negative bacteria include, but are not limited to: Escherichia coli, Salmonella, Enterobacteriaceae, Pseudomonas, Moraxella, Helicobacter, Stenotrophomonas, Legionella, and the like. Typically, by replacing the Bordetella ampG gene with a heterologous ampG gene, the amount of tracheal cytoxin (TCT) produced in the resulting strain expresses less than 1% residual TCT activity. In another aspect, the amount of TCT toxin expressed by the resulting strain is between about 0.6% to 1% residual TCT activity or about 0.4% to 3% residual TCT activity or about 0.3% to 5% residual TCT activity.
- PTX is a major virulence factor responsible for the systemic effects of B. pertussis infections, as well as one of the major protective antigens. Due to its properties, the natural ptx gene can be replaced by a mutated version so that the enzymatically active moiety 51 codes for an enzymatically inactive toxin, but the immunogenic properties of the pertussis toxin are not affected. This can be accomplished by replacing the arginine (Arg) at
position 9 of the sequence with a lysine (Lys) (R9K). Furthermore, a glutamic acid (Glu) at position 129 can be replaced with a glycine (GIy) (E129G). Generally these amino acid positions are involved in substrate binding and catalysis, respectively. In other aspects, other mutations can also be made such as those described in U.S. Pat. No. 6,713,072, incorporated herein by reference, as well as any known or other mutations able to reduce the toxin activity. In one aspect, allelic exchange can first be used to delete the ptx operon and then to insert a mutated version. - In another aspect of the invention, the dnt gene can be removed from the Bordetella strain using allelic exchange. Besides the total removal, the enzymatic activity can also be inhibited by a point mutation. Since DNT is constituted by a receptor-binding domain in the N-terminal region and a catalytic domain in the C-terminal part, a point mutation in the dnt gene to replace Cys-1305 to Ala-1305 inhibits the enzyme activity of DNT (Kashimoto T., Katahira J, Cornejo W R, Masuda M, Fukuoh A, Matsuzawa T, Ohnishi T, Horiguchi Y. (1999) Identification of functional domains of Bordetella dermonecrotizing toxin. Infect. Immun. 67: 3727-32.).
- Besides allelic exchange to insert the mutated ptx gene and the inhibited or deleted dnt gene, the open reading frame of a gene can be interrupted by insertion of a genetic sequence or plasmid. This method is also contemplated in the invention. Other methods of generating mutant strains are generally well known in the art.
- In one aspect of the invention, the mutated strain is called a BPZE1 strain and has been deposited with the Collection Nationale de Cultures de Microorganismes (CNCM) in Paris, France under the Budapest Treaty on Mar. 9, 2006 and assigned the number CNCM 1-3585. The mutations introduced into BPZE1 generally result in attenuation, but also allow the bacteria to colonize and persist. Thus, in another aspect, the invention provides BPZE1, which can induce mucosal immunity and systemic immunity when administered to a mammal in need thereof. In another aspect of the invention, a BPZE1 recombinant strain was constructed which expresses three copies of M2e peptide. This strain has been deposited with the National Measurement Institute (formerly AGAL) in Port Melbourne, Victoria, Australia 3207 under the Budapest Treaty on Apr. 27, 2009, and assigned the following accession number V09/009169. M2e is the extracellular portion of the M2 protein from influenza virus. It is highly conserved among all influenza A viruses and has been shown to induce an antibody-mediated protection against influenza A viruses. The recombinant M2e-producing BPZE1 strain can trigger (for example, upon nasal administration of the live bacteria) substantial anti-M2e antibody responses (local and systemic), allowing a significant protection against H1N1 and H3N2 challenge comparable to the BPZE1 bacteria alone.
- The mutated Bordetella strains of the invention can be used in immunogenic compositions for the treatment or prevention of influenza virus infections. Such immunogenic compositions are useful to raise an immune response, either an antibody response and or a T cell response in mammals. For example, the T cell response can be such that it protects a mammal against influenza infection or against its consequences/diseases/symptoms.
- The mutated Bordetella strains of the invention can be used as live strains in vaccines or immunogenic compositions. In one aspect, the live strains are used for nasal administration, while the chemically- or heat killed strains can be used for systemic or mucosal administration. In other aspects the stains are attenuated.
- In other aspects of the invention, the strains do not include any heterologous genes other than the heterologous ampG gene described above. In yet other aspects, the strains do not include a heterologous expression platform (See, e.g., WO2007104451). Typically, heterologous expression platforms carry heterologous antigens. In one aspect, the heterologous expression platform can be used to deliver the heterologous antigens to the respiratory mucosa of a mammal.
- Compositions of the invention can be administered in conjunction with other immunoregulatory agents, including adjuvants. As used herein, the term “adjuvant” refers to a compound or mixture that enhances an immune response. In particular, compositions can include an adjuvant. Adjuvants for use with the invention can include, but are not limited to, one or more of the following set forth below:
- Mineral containing compositions suitable for use as adjuvants in the invention include mineral salts, such as aluminum salts and calcium salts. The invention includes mineral salts such as hydroxides (e.g., oxyhydroxides), phosphates (e.g., hydroxyphosphates, orthophosphates), sulfates, and the like (e.g., see
chapters 8 & 9 of Vaccine Design . . . (1995) eds. Powell & Newman ISBN: 030644867X. Plenum.), or mixtures of different mineral compounds (e.g., a mixture of a phosphate and a hydroxide adjuvant, optionally with an excess of the phosphate), with the compounds taking any suitable form (e.g., gel, crystalline, amorphous, and the like), and with adsorption to the salt(s) being preferred. The mineral containing compositions can also be formulated as a particle of metal salt (WO/0023105). - Aluminum salts can be included in compositions of the invention such that the dose of Al3 + is between 0.2 and 1.0 mg per dose.
- Oil-emulsion compositions suitable for use as adjuvants in the invention can include squalene-water emulsions, such as MF59 (5% Squalene, 0.5
% TWEEN® 80, and 0.5% SPAN® 85, formulated into submicron particles using a microfluidizer). See, e.g., WO90/14837. See also, Podda, “The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine”, Vaccine 19: 2673-2680, 2001. - In other related aspects, adjuvants for use in the compositions are submicron oil-in-water emulsions. Examples of submicron oil-in-water emulsions for use herein include squalene/water emulsions optionally containing varying amounts of MTP-PE, such as a submicron oil-in-water emulsion containing 4-5% w/v squalene, 0.25-1.0% w/v TWEEN® 80 (polyoxyelthylenesorbitan monooleate), and/or 0.25-1.0% SPAN® 85 (sorbitan trioleate), and, optionally, N-acetylmuramyl-L-alanyl-D-isogluatminyl-L-alanine-2-(F-2′-dipalmitoyl-s-n-glycero-3-huydroxyphosphophoryloxy)-ethylamine (MTP-PE), for example, the submicron oil-in-water emulsion known as “MF59” (International Publication No. WO90/14837; U.S. Pat. Nos. 6,299,884 and 6,451,325, incorporated herein by reference in their entirety; and Ott et al., “MF59—Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines” in Vaccine Design: The Subunit and Adjuvant Approach (Powell, M. F. and Newman, M. J. eds.) Plenum Press, New York, 1995, pp. 277-296). MF59 can contain 4-5% w/v Squalene (e.g., 4.3%), 0.25-0.5% w/
v TWEEN® 80, and 0.5% w/v SPAN® 85 and optionally contains various amounts of MTP-PE, formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA). For example, MTP-PE can be present in an amount of about 0-500 μg/dose, or 0-250 μg/dose, or 0-100 μg/dose. - Submicron oil-in-water emulsions, methods of making the same and immunostimulating agents, such as muramyl peptides, for use in the compositions, are described in detail in International Publication No. WO90/14837 and U.S. Pat. Nos. 6,299,884 and 6,451,325, incorporated herein by reference in their entirety.
- Complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA) can also be used as adjuvants in the invention.
- Saponin formulations, can also be used as adjuvants in the invention. Saponins are a heterologous group of sterol glycosides and triterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species. Saponin from the bark of the Quillaia saponaria Molina tree have been widely studied as adjuvants. Saponin can also be commercially obtained from Smilax ornata (sarsaprilla), Gypsophilla paniculata (brides veil), and Saponaria officianalis (soap root). Saponin adjuvant formulations can include purified formulations, such as QS21, as well as lipid formulations, such as Immunostimulating Complexs (ISCOMs; see below).
- Saponin compositions have been purified using High Performance Thin Layer Chromatography (HPLC) and Reversed Phase High Performance Liquid Chromatography (RP-HPLC). Specific purified fractions using these techniques have been identified, including QS7, QS17, QS18, QS21, QH-A, QH-B and QH-C. A method of production of QS21 is disclosed in U.S. Pat. No. 5,057,540. Saponin formulations can also comprise a sterol, such as cholesterol (see WO96/33739).
- Combinations of saponins and cholesterols can be used to form unique particles called ISCOMs. ISCOMs typically also include a phospholipid such as phosphatidylethanolamine or phosphatidylcholine. Any known saponin can be used in ISCOMs. For example, an ISCOM can include one or more of Quil A, QHA and QHC. ISCOMs are further described in EP0109942, WO96/11711, and WO96/33739. Optionally, the ISCOMS can be devoid of additional detergent. See WO00/07621.
- A description of the development of saponin based adjuvants can be found at Barr, et al., “ISCOMs and other saponin based adjuvants”, Advanced Drug Delivery Reviews 32: 247-27, 1998. See also Sjolander, et al., “Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines”, Advanced Drug Delivery Reviews 32: 321-338, 1998.
- Virosomes and Virus Like Particles (VLPs) can also be used as adjuvants in the invention. These structures generally contain one or more proteins from a virus optionally combined or formulated with a phospholipid. They are generally non-pathogenic, non-replicating and generally do not contain any of the native viral genome. The viral proteins can be recombinantly produced or isolated from whole viruses. These viral proteins suitable for use in virosomes or VLPs include proteins derived from influenza virus (such as HA or NA), Hepatitis B virus (such as core or capsid proteins), Hepatitis E virus, measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth Disease virus, Retrovirus, Norwalk virus, human Papilloma virus, HIV, RNA-phages, QB-phage (such as coat proteins), GA-phage, fr-phage, AP205 phage, and Ty (such as retrotransposon Ty protein pl).
- Adjuvants suitable for use in the invention include bacterial or microbial derivatives such as:
- (1) Non-Toxic Derivatives of Enterobacterial Lipopolysaccharide (LPS)
- Such derivatives include Monophosphoryl lipid A (MPL) and 3-O-deacylated MPL (3 dMPL). 3 dMPL is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains. An example of a “small particle” form of 3 De-O-acylated monophosphoryl lipid A is disclosed in
EP 0 689 454. Such “small particles” of 3 dMPL are small enough to be sterile filtered through a 0.22 micron membrane (seeEP 0 689 454). Other non-toxic LPS derivatives include monophosphoryl lipid A mimics, such as aminoalkyl glucosaminide phosphate derivatives e.g., RC-529. See Johnson et al., Bioorg Med Chem Lett 9: 2273-2278, 1999. - (2) Lipid A Derivatives
- Lipid A derivatives can include derivatives of lipid A from Escherichia coli such as OM-174. OM-174 is described for example in Meraldi et al., “OM-174, a New Adjuvant with a Potential for Human Use, Induces a Protective Response with Administered with the Synthetic C-Terminal Fragment 242-310 from the circumsporozoite protein of Plasmodium berghei”, Vaccine 21: 2485-2491, 2003; and Pajak, et al., “The Adjuvant OM-174 induces both the migration and maturation of murine dendritic cells in vivo”, Vaccine 21: 836-842, 2003.
- (3) Immunostimulatory Oligonucleotides
- Immunostimulatory oligonucleotides suitable for use as adjuvants in the invention can include nucleotide sequences containing a CpG motif (a sequence containing an unmethylated cytosine followed by guanosine and linked by a phosphate bond). Bacterial double stranded RNA or oligonucleotides containing palindromic or poly(dG) sequences have also been shown to be immunostimulatory.
- The CpG's can include nucleotide modifications/analogs such as phosphorothioate modifications and can be double-stranded or single-stranded. Optionally, the guanosine can be replaced with an analog such as 2′-deoxy-7-deazaguanosine. See Kandimalla, et al., “Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles”, Nucleic Acids Research 31: 2393-2400, 2003; WO02/26757 and WO99/62923 for examples of analog substitutions. The adjuvant effect of CpG oligonucleotides is further discussed in Krieg, “CpG motifs: the active ingredient in bacterial extracts?”, Nature Medicine (2003) 9(7): 831-835; McCluskie, et al., “Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA”, FEMS Immunology and Medical Microbiology (2002) 32:179-185; WO98/40100; U.S. Pat. Nos. 6,207,646; 6,239,116 and 6,429,199.
- The CpG sequence can be directed to Toll-like receptor (TLR9), such as the motif GTCGTT or TTCGTT. See Kandimalla, et al., “Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs”, Biochemical Society Transactions (2003) 31 (part 3): 654-658. The CpG sequence can be specific for inducing a Th1 immune response, such as a CpG-A ODN, or it can be more specific for inducing a B cell response, such a CpG-B ODN. CpG-A and CpG-B ODNs are discussed in Blackwell, et al., “CpG-A-Induced Monocyte IFN-gamma-Inducible Protein-10 Production is Regulated by Plasmacytoid Dendritic Cell Derived IFN-alpha”, J. Immunol. 170: 4061-4068, 2003; Krieg, “From A to Z on CpG”, TRENDS in Immunology 23: 64-65, 2002, and WOO1/95935.
- In some aspects, the CpG oligonucleotide can be constructed so that the 5′ end is accessible for receptor recognition. Optionally, two CpG oligonucleotide sequences can be attached at their 3′ ends to form “immunomers”. See, for example, Kandimalla, et al., “Secondary structures in CpG oligonucleotides affect immunostimulatory activity”, BBRC 306: 948-95, 2003; Kandimalla, et al., “Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic GpG DNAs”, Biochemical Society Transactions 31: 664-658, 2003; Bhagat et al., “CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents” BBRC 300: 853-861, 2003, and WO03/035836.
- (4) ADP-Ribosylating Toxins and Detoxified Derivatives Thereof.
- Bacterial ADP-ribosylating toxins and detoxified derivatives thereof can be used as adjuvants in the invention. For example, the toxin can be derived from E. coli (i.e., E. coli heat labile enterotoxin (LT)), cholera (CT), or pertussis (PTX). The use of detoxified ADP-ribosylating toxins as mucosal adjuvants is described in WO95/17211 and as parenteral adjuvants in WO98/42375. In some aspects, the adjuvant can be a detoxified LT mutant such as LT-K63, LT-R72, and LTR192G. The use of ADP-ribosylating toxins and detoxified derivaties thereof, particularly LT-K63 and LT-R72, as adjuvants can be found in the following references, each of which is specifically incorporated by reference herein in their entirety: Beignon, et al., “The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enahnces the Ability of Peptide Antigens to Elicit CD4+T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin”, Infection and Immunity 70: 3012-3019, 2002; Pizza, et al., “Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants”, Vaccine 19: 2534-2541, 2001; Pizza, et al., “LTK63 and LTR72, two mucosal adjuvants ready for clinical trials” Int. J. Med. Microbiol 290: 455-461, 2003; Scharton-Kersten et al., “Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits and Unrelated Adjuvants”, Infection and Immunity 68: 5306-5313, 2000; Ryan et al., “Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells” Infection and Immunity 67: 6270-6280, 2003; Partidos et al., “Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides”, Immunol. Lett. 67: 09-216, 1999; Peppoloni et al., “Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines”, Vaccines 2: 285-293, 2003; and Pine et al., (2002) “Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63)” J. Control Release 85: 263-270, 2002. Numerical reference for amino acid substitutions is preferably based on the alignments of the A and B subunits of ADP-ribosylating toxins set forth in Domenighini et al., Mol. Microbiol 15: 1165-1167, 1995, specifically incorporated herein by reference in its entirety.
- Bioadhesives and mucoadhesives can also be used as adjuvants in the invention. Suitable bioadhesives can include esterified hyaluronic acid microspheres (Singh et al., J. Cont. Rele. 70:267-276, 2001) or mucoadhesives such as cross-linked derivatives of poly(acrylic acid), polyvinyl alcohol, polyvinyl pyrollidone, polysaccharides and carboxymethylcellulose. Chitosan and derivatives thereof can also be used as adjuvants in the invention. See, for example, WO99/27960.
- Microparticles can also be used as adjuvants in the invention. Microparticles (i.e., a particle of about 100 nm to about 150 μm in diameter, or 200 nm to about 30 μm in diameter, or about 500 nm to about 10 μm in diameter) formed from materials that are biodegradable and/or non-toxic (e.g., a poly(alpha-hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone, and the like), with poly(lactide-co-glycolide) are envisioned, optionally treated to have a negatively-charged surface (e.g., with SDS) or a positively-charged surface (e.g., with a cationic detergent, such as CTAB).
- Examples of liposome formulations suitable for use as adjuvants are described in U.S. Pat. Nos. 6,090,406, 5,916,588, and
EP 0 626 169. - I. Polyoxyethylene Ether and Polyoxyethylene Ester Formulations
- Adjuvants suitable for use in the invention can also include polyoxyethylene ethers and polyoxyethylene esters. WO99/52549. Such formulations can further include polyoxyethylene sorbitan ester surfactants in combination with an octoxynol (WO01/21207) as well as polyoxyethylene alkyl ethers or ester surfactants in combination with at least one additional non-ionic surfactant such as an octoxynol (WO01/21152).
- In some aspects, polyoxyethylene ethers can include: polyoxyethylene-9-lauryl ether (laureth 9), polyoxyethylene-9-steoryl ether, polyoxytheylene-8-steoryl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, or polyoxyethylene-23-lauryl ether.
- PCPP formulations for use as adjuvants are described, for example, in Andrianov et al., “Preparation of hydrogel microspheres by coacervation of aqueous polyphophazene solutions”, Biomaterials 19: 109-115, 1998, and Payne et al., “Protein Release from Polyphosphazene Matrices”, Adv. Drug. Delivery Review 31: 185-196, 1998.
- Examples of muramyl peptides suitable for use as adjuvants in the invention can include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-1-alanyl-d-isoglutamine (nor-MDP), and N-acetylmuramyl-1-alanyl-d-isoglutaminyl-1-alanine-2-(1′-2′-dipalmitoyl-s-n-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE).
- Examples of imidazoquinolone compounds suitable for use as adjuvants in the invention can include Imiquimod and its homologues, described further in Stanley, “Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential” Clin Exp Dermatol 27: 571-577, 2002 and Jones, “Resiquimod 3M”, Curr Opin Investig Drugs 4: 214-218, 2003.
- Human immunomodulators suitable for use as adjuvants in the invention can include cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, and the like), interferons (e.g., interferon-gamma), macrophage colony stimulating factor, and tumor necrosis factor.
- The invention can also comprise combinations of aspects of one or more of the adjuvants identified above. For example, adjuvant compositions can include:
-
- (1) a saponin and an oil-in-water emulsion (WO99/11241);
- (2) a saponin (e.g., QS21)+a non-toxic LPS derivative (e.g., 3 dMPL) (see WO94/00153);
- (3) a saponin (e.g., QS21)+a non-toxic LPS derivative (e.g., 3 dMPL)+a cholesterol;
- (4) a saponin (e.g., QS21)+3 dMPL+IL-12 (optionally+a sterol) (WO98/57659);
- (5) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions (See European patent applications 0835318, 0735898 and 0761231);
- (6) SAF, containing 10% Squalane, 0.4
% TWEEN® - (7) Ribi adjuvant system (RAS), (Ribi Immunochem) containing 2% Squalene, 0.2
% TWEEN® 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (Detox); and - (8) one or more mineral salts (such as an aluminum salt)+a non-toxic derivative of LPS (such as 3 dPML).
- Aluminum salts and MF59 are examples of adjuvants for use with injectable influenza vaccines. Bacterial toxins and bioadhesives are examples of adjuvants for use with mucosally-delivered vaccines, such as nasal vaccines. All adjuvants noted above and others as generally known in the art to one of ordinary skill can be formulated for intranasal administration using techniques well known in the art.
- Methods for treatment or prevention of diseases related to influenza virus infection (described in more detail below) are also encompassed by the invention. Said methods of the invention include administering a therapeutically effective amount of a composition of the invention. The composition of the invention can be formulated in pharmaceutical compositions. These compositions can comprise, in addition to one or more of the strains, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer, or other materials well known to those skilled in the art. Such materials should typically be non-toxic and should not typically interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material can depend on the route of administration, e.g., oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, or intraperitoneal routes.
- Pharmaceutical compositions for oral administration can be in tablet, capsule, powder or liquid form. A tablet can include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil, or synthetic oil. Physiological saline solution, dextrose, or other saccharide solution or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol can be included.
- For intravenous, cutaneous, or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity, and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, or Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants, and/or other additives can be included, as required.
- Administration is preferably in a “therapeutically effective amount” or “prophylactically effective amount” (as the case can be, although prophylaxis can be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of disease being treated. Prescription of treatment, e.g., decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in the latest edition of Remington's Pharmaceutical Science, Mack Publishing Company, Easton, PA (“Remington's”).
- Typically, a composition can be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
- Compositions of the invention will generally be administered directly to a mammal Direct delivery can be accomplished by parenteral injection (e.g., subcutaneously, intraperitoneally, intradermal, intravenously, intramuscularly, or to the interstitial space of a tissue), or mucosally, such as by rectal, oral (e.g., tablet, spray), vaginal, topical, transdermal (See e.g., WO99/27961) or transcutaneous (See e.g., WO02/074244 and WO02/064162), inhalation, intranasal (See e.g., WO03/028760), ocular, aural, pulmonary or other mucosal administration. Compositions can also be administered topically by direct transfer to the surface of the skin. Topical administration can be accomplished without utilizing any devices, or by contacting naked skin with the composition utilizing a bandage or a bandage-like device (see, e.g., U.S. Pat. No. 6,348,450).
- In some aspects, the mode of administration is parenteral, mucosal, or a combination of mucosal and parenteral immunizations. In other aspects, the mode of administration is parenteral, mucosal, or a combination of mucosal and parenteral immunizations in a total of 1-2 vaccinations 1-3 weeks apart. In related aspects, the route of administration includes but is not limited to intranasal delivery.
- The invention can include administration of a mutated Bordetella strain to a mammal to elicit an immune response (e.g., a TH1 immune response) capable of impacting an influenza virus, e.g., H3N2. Examples of mutated Bordetella strains of the invention are described above. Typically, administration of the mutated Bordetella strain is used to treat or prevent an influenza virus infection in a mammal, e.g., a human, via protective immunity against the influenza virus. In some aspects, the mutated Bordetella strain administration is used to prevent influenza infection by administration prior to the influenza virus infection. Typically, the mutated Bordetella stain is administered to a mammal about less than 1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks prior to the influenza virus infection.
- In one aspect, the method for treating or preventing an infection by an influenza virus includes administering to a subject in need thereof a single dose of a composition of the invention, e.g., BPZE1. In related aspects, the administering step is performed mucosally, e.g., intranasally.
- In other aspects, composition of the invention is administered in more than one dose, e.g., two doses. The number of doses can vary as needed, for example the number of doses administered to a mammal can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses. In one aspect, the method for treating or preventing an infection by an influenza virus, includes administering to a subject in need thereof a first immunogenic composition of the invention (comprising e.g., BPZE1) followed by a second immunogenic composition administration (comprising e.g., BPZE1). Typically, the time range between each dose of the composition can be about 1-6 days, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, or more weeks. In related aspects, the time range between each dose is about 3 weeks. In other aspects, prime-boost-style methods can be employed where a composition of the invention can be delivered in a “priming” step and, subsequently, a composition of the invention is delivered in a “boosting” step.
- The composition can typically be used to elicit systemic and/or mucosal immunity, for example to elicit an enhanced systemic and/or mucosal immunity. For example, the immune response can be characterized by the induction of a serum IgG and/or intestinal IgA immune response. Typically, the level of protection against influenza infection can be more than 50%, e.g., 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more. In one aspect, the level of protection can be 100%. In other aspects the level of protection is less than 50%, e.g., 20%. In other aspects, the number of bacteria in each dosage is adjusted to attain an effective immune response in a mammal. The number of bacteria or cfus in each dosage can be about 1, 10, 100, 1000, 10000, 100000, 1000000, 5×106, or more or any dosage between said each dosage.
- In other aspects the invention can also include co-administration of the composition with another agent or agents. Typically, the various compositions/agents can be delivered in any order. Thus, in aspects including delivery of multiple different compositions or agents, the mutated Bordetella strain need not be all delivered before the agent, e.g., a drug, a siRNA, a miRNA, an immunogenic peptide, or a small molecule capable of effecting an influenza infection. Other examples of agents include neuraminidase inhibitors and M2 inhibitors (adamantanes). For example, the priming step can include delivery of one or more agents and the boosting can include delivery of one or more mutated Bordetella strains. In other aspects, multiple administrations of mutated Bordetella strains can be followed by multiple administrations of agents. Administrations can be performed in any order. Thus, one or more of the mutated Bordetella strains described herein and one or more agents can be co-administered in any order and via any administration route known in the art, e.g., to elicit an immune reaction.
- In the invention, dosage treatment can be according to a single dose schedule or a multiple dose schedule. For example, multiple doses can be used in a primary immunization schedule and/or in a booster immunization schedule. In a multiple dose schedule, the various doses can be given by the same or different routes, e.g., a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, and the like. In other aspects, the dosage regime can enhance the avidity of the antibody response leading to antibodies with a neutralizing characteristic. An in-vitro neutralization assay can be used to test for neutralizing antibodies (see for example Asanaka et al, J Virology 102: 10327, 2005; Wobus et al.,
PLOS Biology 2; e432; and Dubekti et al., J Medical Virology 66: 400). - One way of assessing efficacy of therapeutic treatment involves monitoring infection after administration of a composition of the invention. One way of assessing efficacy of prophylactic treatment involves monitoring immune responses against the antigens in the compositions of the invention after administration of the composition. Another way of assessing the immunogenicity of the compositions of the invention is to isolate the proteins or proteins mixes and to screen patient sera or mucosal secretions by immunoblot. A positive reaction between the protein and the patient serum indicates that the patient has previously mounted an immune response to the composition.
- Another way of checking efficacy of therapeutic treatment involves monitoring infection after administration of the compositions of the invention. One way of checking efficacy of prophylactic treatment involves monitoring immune responses both systemically (such as monitoring the level of IgG1 and IgG2a production) and mucosally (such as monitoring the level of IgA production) against the antigens in the compositions of the invention after administration of the composition. Typically, serum specific antibody responses are determined post-immunization but pre-challenge whereas mucosal specific antibody responses are determined post-immunization and post-challenge. The immunogenic compositions of the invention can be evaluated in in vitro and in vivo animal models prior to host, e.g., human, administration.
- The efficacy of compositions of the invention can also be determined in vivo by challenging animal models of infection, e.g., mice, with the compositions. The compositions can or cannot be derived from the same strains as the challenge strains. In vivo efficacy models can include but are not limited to: (i) A murine infection model using human strains; (ii) a murine disease model which is a murine model using a mouse-adapted strain, such as strains which are particularly virulent in mice; and (iii) a primate model using human isolates.
- The immune response induced by the invention can be one or both of a TH1 immune response and a TH2 response. The immune response can be an improved or an enhanced or an altered immune response. The immune response can be one or both of a systemic and a mucosal immune response. For example, the immune response can be an enhanced systemic and/or mucosal response. An enhanced systemic and/or mucosal immunity is reflected in an enhanced TH1 and/or TH2 immune response. For example, the enhanced immune response can include an increase in the production of IgG1 and/or IgG2a and/or IgA. In another aspect the mucosal immune response can be a TH2 immune response. For example, the mucosal immune response can include an increase in the production of IgA.
- Typically, activated TH2 cells enhance antibody production and are therefore of value in responding to extracellular infections. Activated TH2 cells can typically secrete one or more of IL-4, IL-5, IL-6, and IL-10. A TH2 immune response can also result in the production of IgG1, IgE, IgA, and/or memory B cells for future protection. In general, a TH2 immune response can include one or more of an increase in one or more of the cytokines associated with a TH2 immune response (such as IL-4, IL-5, IL-6 and IL-10), or an increase in the production of IgG1, IgE, IgA and memory B cells. For example, an enhanced TH2 immune response can include an increase in IgG1 production.
- A TH1 immune response can include one or more of an increase in CTLs, an increase in one or more of the cytokines associated with a TH1 immune response (such as IL-2, IFN-gamma, and TNF-alpha), an increase in activated macrophages, an increase in NK activity, or an increase in the production of IgG2a. For example, the enhanced TH1 immune response can include an increase in IgG2a production.
- Compositions of the invention, in particular, an immunogenic composition comprising one or more strains of the invention can be used either alone or in combination with other agents optionally with an immunoregulatory agent capable of eliciting a Th1 and/or Th2 response.
- The compositions of the invention can elicit both a cell-mediated immune response as well as a humoral immune response to effectively address an influenza infection. This immune response will preferably induce long lasting (e.g., neutralizing) antibodies and a cell-mediated immunity that can quickly respond upon exposure to one or more infectious antigens in the future.
- Compositions of the invention are typically for preventing or treating influenza virus strains in mammalian subjects, e.g., humans. In some aspects, subjects can include the elderly (e.g., >65 years old), children (e.g., <5 years old), hospitalized patients, healthcare workers, armed service and military personnel, food handlers, pregnant women, the chronically ill, and people traveling abroad. The compositions are generally suitable for these groups as well as the general population or as otherwise deemed necessary by a physician.
- The invention also provides kits comprising one or more containers of compositions of the invention. Compositions can be in liquid form or can be lyophilized. Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes. Containers can be formed from a variety of materials, including glass or plastic. A container can have a sterile access port (for example, the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- The kit can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery device(s). The kit can further include a third component comprising an adjuvant.
- The kit can also comprise a package insert containing written instructions for methods of inducing immunity, preventing infections, or for treating infections. The package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body.
- The invention also provides a delivery device pre-filled with the compositions of the invention.
- The pharmaceutical compositions are generally formulated as sterile, substantially isotonic and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.
- From the foregoing description, various modifications and changes in the compositions and methods will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein. Each recited range includes all combinations and sub-combinations of ranges, as well as specific numerals contained therein.
- Although the foregoing invention has been described in detail by way of example for purposes of clarity of understanding, it will be apparent to the artisan that certain changes and modifications are comprehended by the disclosure and can be practiced without undue experimentation within the scope of the appended claims, which are presented by way of illustration not limitation.
- Below are examples of specific aspects for carrying out the invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, and the like), but some experimental error and deviation should, of course, be allowed for.
- The practice of the invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T. E. Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's; Carey and Sundberg
Advanced Organic Chemistry 3rd Ed. (Plenum Press) Volumes A and B, 1992). - The bacterial strain used in this study is B. pertussis BPZE1, a streptomycin-resistant Tohamal derivative deleted for the dermonecrotic (DNT)-encoding gene, producing inactivated pertussis toxin (PT) and background levels of tracheal cytotoxin (TCT) (22). BPZE1 bacteria were grown at 37° C. for 72 h on Bordet-Gengou (BG) agar (Difco, Detroit, Mich.) supplemented with 1% glycerol, 10% defibrinated sheep blood and 100 μg/ml streptomycin (Sigma Chemical CO., St Louis, Mo.). Liquid cultures were performed as described previously (Menozzi F D, et al., “Identification and purification of transferring- and lactoferrin-binding proteins of Bordetella pertussis and Bordetella bronchiseptica”, Infect. Immun 59: 3982-3988, 1991) in Stainer-Scholte (SS) medium containing 1 g/l heptakis(2,6-di-o-methyl) β-cyclodextrin (Sigma). Heat-inactivation was performed at 95° C. for 1 hour.
- Intranasal Infections. Six to eight week-old female Balb/c mice were kept under specific pathogen-free conditions in Individual Ventilated Cages, and all experiments were carried out under the guidelines of the National University of Singapore animal study board. For BPZE1 treatment, sedated mice were intranasally administered once, twice or three times (as indicated) with approximately 5×106 colony-forming units (cfu) of live or dead BPZE1 bacteria in 20 μl sterile PBS supplemented with 0.05% TWEEN® 80 (Sigma) (PBST) as previously described (Mielcarek N, et al., “Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen”, Infect immune 65: 544-550, 1997). For influenza infection, sedated mice were nasally administered with approximately 2×106 TCID50 of mouse-adapted A/Aichi/2/68 (H3N2) virus passage 10 (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009) or 4 lethal dose (LD)50 of H1N1 (A/PR/8/34) influenza virus (ATCC #VR-95) in 20 μl sterile PBS supplemented with penicillin and streptomycin. Ten mice per group were used to determine the survival rates based on body weight loss and the mice were euthanized when body weight loss exceeded 20% of the original body weight.
- Mouse lungs were harvested and homogenized using mechanical disruption (Omni homogenizer), and tested for the presence of viable virus by tissue culture infectious dose 50 (TCID50) assay using a modified method reported by the WHO (WHO, “WHO Manual on Animals Influenza Diagnosis and Surveillance” (World Health Organization, Geneva), 2002). Briefly, 90% confluent Madin-Darby Canine Kidney (MDCK) cells in 96-well plates were inoculated with 100 μl of 10-fold serially diluted lung homogenates. Plates were incubated at 35° C. in a humidified incubator (5% CO2) for 3 days. TCID50 was determined by a reduction in cytopathic effect (CPE) of 50%, and the log TCID50/lung was derived. Five mice per group per time point were individually assessed.
- Four mice per group were sacrificed and their lungs were harvested 3 days post-viral challenge. The lungs were removed and fixed in 10% formalin in PBS. After fixation, the lungs were embedded in paraffin, sectioned, and stained with H&E.
- Individual BALFs were recovered by injecting 1 ml of sterile PBS into the lungs of sacrificed animals and performing one lavage step ensuring that both lungs inflated during the process. BALFs were then centrifuged at 400 g for 10 min, and the supernatant was removed and stored at −80° C. for cytokine detection. Total BALF cell number was determined using a hemocytometer. The cells were spotted onto a glass slide using a Cytospin device (Thermo Shandon), and were stained with a modified Wright staining procedure (Kimman T G, et al., “Development and antigen specificity of the lymphoproliferation response of pigs to pseudorabies virus: dichotomy between secondary B- and T-cell responses”, Immunology 86: 372-378, 1995). Identification of the different cell types was performed using standard morphological criteria. Results are expressed as the percentage of each cell type in the total cell population. A total of 500 cells were considered per slide. Four mice per group were individually assessed.
- Mice were sacrificed, their lungs were harvested and single cell suspensions were prepared by digesting the lungs at 37° C. for 15 min in 2 ml digestion buffer containing 0.5 mg/ml Liberase (Roche) in RPMI with 1% FCS and 2 U/ml DNaseI (Qiagen), followed by centrifugation on Ficoll-Paque™PLUS (GE) for 20 min at 600 g and room temperature. Cells were collected and washed twice with sterile FACS buffer (2% FCS, 5 mM EDTA in PBS). 106 cells were stained with FITC-labeled anti-mouse CD3 antibody (eBioscience) and analyzed on CyAn™ ADP cytometer (Dako). Five mice per group per time point were individually assessed.
- Cytokine and chemokine production in the BALFs supernatants was measured using Procarta cytokine profiling kit, according to the manufacturer's instructions (Panomics). After incubation with Ab-conjugated beads, detection Abs and streptavidin-PE complexes, samples were run on Bio-Plex instrument (Bio-Rad). Levels of the following growth factors, cytokines, and inflammatory mediators were evaluated: GM-CSF, KC, IL-1β, IL-6, IFN-γ and TNF-α, IFN-α, MCP-1 RANTES, IL-10. In addition, TGF-β levels were measured using a Human/Mouse TGFβ1 ELISA kit (eBioscience) according to the manufacturer's instructions.
- A high titer anti-B. pertussis immune serum was generated in 10 adult Balb/c mice nasally infected twice at a 4-week interval with 5×106 cfu of live BPZE1 bacteria. Another group of 10 adult naïve Balb/c mice were injected intraperitoneally (ip.) with 105.5 TCID50 of heat-inactivated human/Aichi/2/68 (H3N2) virus (HI-H3N2) in complete Freund's adjuvant and boosted with the same amount of HI-H3N2 virus in incomplete Freund's adjuvant 2 weeks later. The immune sera from each mouse group were collected 2 weeks after the boost, pooled and the anti-pertussis and anti-influenza antibody titers were measured by ELISA. Moreover, HI-H3N2 serum was tested for the presence of neutralizing antibodies by neutralization assay. The immune sera were filter-sterilized, heat inactivated at 56° C. for 30 min and stored at −80° C. until further use. Sera from control naïve mice were also collected as negative control.
- Six to eight week-old recipient Balb/c mice were ip. injected with 200 μl of naïve, anti-BPZE1 or anti-H3N2
immune serum 1 day prior viral challenge with mouse-adapted H3N2 virus. Body weight losses were monitored to determine the survival rates. Ten mice per group were assayed. - Lymphocyte proliferation was measured by incorporation of tritiated (3H) thymidine as described elsewhere (Bao Z, et al., “Glycogen synthase kinase-3beta inhibition attenuates asthma in mice”, Am J Respir Crit Care Med 176: 431-438, 2007). Briefly, spleens from naïve and BPZE1-treated mice (6 mice per group) were collected under aseptic condition and pooled. Single-cell suspensions were prepared and centrifuged on Ficoll-Paque™PLUS (GE) for 20 min at 600 g at room temperature. The isolated splenocytes were seeded in 96-well round-bottom plates (NUNC) at a density of 2×105 cells/well in 100 μl medium (RPMI640 supplemented with 10% FCS, 5×10-5 M β-mercaptoethanol, 2 mM L-glutamine, 10 mM HEPES, 200 U/ml penicillin, 200 μg/ml streptomycin). 100 μl medium containing 20 μg/ml of BPZE1 whole cell lysate or heat-inactivated 105 TCID50 mouse-adapted H3N2 influenza virus (HI-H3N2) (test antigen) were added to the splenocytes. 100 ul of non-infected egg amniotic fluid and 100 ul of medium containing 5 μg/ml concanavalin A (conA) were used as mock and vitality controls, respectively. After 3 days of incubation at 37° C. in 5% CO2 atmosphere, the cultures were pulsed with 0.4 μCi [3H]thymidine in 20 μl RPMI complete medium. After 18 hrs incubation, cells were harvested, washed and the incorporated radioactivity was measured in TopCount NXT™ Microplate Scintillation and Luminescence Counter (PerkinElmer). Results are expressed as stimulation index (SI) corresponding to the ratio between the mean of [3H]thymidine uptake in the presence of test antigen and the mean of [3H]thymidine uptake in the absence of test antigen. A SI>2 was considered positive. Each sample was assayed in quadruplicate.
- The frequency of antigen-specific IFN-γ-producing splenocytes was determined by ELISPOT assay using BD mouse ELISPOT set (BD PharMingen) according to the manufacturer's instructions. Briefly, single-cell suspensions of individual spleen from naïve and BPZE1-treated mice were prepared and plated in 96-well microplates (Millipore, Bedford, MA) pre-coated with 100 μl of [5 μg/ml anti-IFN-γ antibody in sterile PBS] overnight at 4° C., washed three times and blocked for 2 hr at room temperature with RPMI 1640 containing 10% FCS. Cells were then incubated with 20 μg/ml of BPZE1 whole cell lysate or heat-inactivated 105 TCID50 mouse-adapted H3N2 influenza virus (HI-H3N2) or 5 μg/ml conA for 12-20 hr at 37° C. in 5% CO2 atmosphere. The plates were then washed followed by addition of biotin-conjugated anti-mouse IFN-γ antibody for 2 hr at room temperature. After washing, streptavidin-HRP conjugate was added and incubated at room temperature for 1 hr. Wells were washed again and developed with a 3-amino-9-ethyl-carbazole (AEC) substrate solution until spots were visible. After drying, spot-forming cell numbers were counted by Bioreader® 4000 (Biosystem). Six animals per group were individually assayed.
- Unless otherwise stated, bars represent means±SD and averages were compared using a bidirectional unpaired Student's t test with a 5% significance level with * p<0.05, **p≤0.01 and ***p<0.001.
- A mouse-adapted H3N2 influenza virus was obtained through successive lung-to-lung passages of the A/Aichi/2/68 (H3N2) virus into adult Balb/c mice (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009). Passage 10 (P10) strain exhibited high virulence, causing extra-pulmonary spread with necrotic and inflammatory lesions in the various organs of the infected animals Nasal administration of 2×106 TCID50 of the P10 viral suspension caused the death of the animals within 4 days (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009).
- Adult Balb/c mice were nasally inoculated with live BPZE1 bacteria and subsequently challenged either 3 or 6 weeks later with a lethal dose of mouse-adapted H3N2 virus. Survival rate based on body weight changes indicated that the mice challenged 3 weeks after nasal BPZE1 treatment were not significantly protected whereas 60% protection was achieved when mice were challenged 6 weeks post-BPZE1 treatment (
FIG. 1 ). - Adult Balb/c mice were nasally administered once with live or dead BPZE1 bacteria and were subsequently challenged with a lethal dose of mouse-adapted
H3N2 virus 6 weeks post-BPZE1 treatment. The results showed that dead bacteria did not provide any significant protection against H3N2 (FIG. 2 ), suggesting that bacterial colonization of the mouse lung is necessary to induce the protective mechanisms. - Live BPZE1 bacteria were nasally administered to Balb/c mice twice at a 4-week interval prior lethal challenge with mouse-adapted H3N2 virus performed 4 weeks after the last BPZE1 administration. A 100% protection rate was obtained for the BPZE1-treated animals with minimal body weight changes (
FIG. 3 ). Similar protection rate was achieved when the viral challenge was performed 2 weeks after the boost. These data indicated that a second nasal administration of live BPZE1 bacteria not only enhanced the protection efficacy but also shortened the time necessary to trigger the protective mechanisms. - The protective potential of BPZE1 bacteria against influenza A viruses was further explored. Mice nasally treated once with live BPZE1 bacteria were not protected against a lethal challenge with human A/PR/8/34 (H1N1) influenza A virus performed 6 weeks later (data not shown). However, three consecutive administrations of live BPZE1 bacteria conferred 50% protection against H1N1 virus (
FIG. 4 ). These observations indicated that BPZE1 bacteria can have the potential to protect against all influenza A viruses although with a variable efficacy. - To further characterize the cross-protection against influenza A viruses, the viral load was quantified in the lungs of mice treated twice with BPZE1 bacteria and in control mice. The virus load was checked 3 days post-infection which corresponds to the peak of virus titer in mice infected with mouse-adapted H3N2 virus (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009). No significant difference in the viral load was observed between the two animal groups (
FIG. 5 ). This result suggested that the cross-protective mechanisms triggered in the BPZE1-treated animals do not directly target the virus particles and/or infected cells. - Lung immunopathology was examined by histology of lung sections from infected BPZE1-treated animals and control mice. As expected and as described previously (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009), the infected control mice displayed severe inflammation with inflammatory cells, severe bronchopneumonia and interstitial pneumonitis with bronchioles and alveoli filled with necrotic debris as well as high pulmonary emphysema and moderate edema (
FIG. 7A ). In contrast, only mild inflammation, minimal airway and alveolar damage, and mild perivascular/peribronchular damage associated with minimal edema were observed in the lungs of the protected BPZE1-treated mice. - The cell populations present in the broncho-alveolar lavage fluids (BALFs) recovered from protected and non-protected animals were also examined Whereas the total number of cells present in the BALFs from both animal groups were comparable (11.8×105 versus 16.1×105), a significantly higher number of macrophages and lower number of neutrophils were found in the BPZE1-treated mice (
FIG. 6B ). - Furthermore, the lymphocyte population present in the lungs of protected and non-protected mice was analysed. Lymphocyte depletion has indeed been reported in mice infected with highly pathogenic H1N1(1918) and H5N1 influenza viruses (Kash J C, et al., “Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus”, Nature 443: 578-581, 2006; Uiprasertkul M, et al., “Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans”, Emerg Infect Dis 13: 708-712, 2007; Lu X, et al., “A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans”, J Virol 73: 5903-5911, 1999) as well as in mice infected with the mouse-adapted H3N2 virus strain used in this work (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009). Here, Balb/c mice were treated twice with BPZE1 bacteria and challenged with mouse-adapted
H3N2 virus 4 weeks later. The mouse lungs were harvested 3 and 5 days post-influenza challenge for FACS analysis of the T cell population. Three days post-viral challenge, the percentage of CD3+ T lymphocytes in the infected control mice and BPZE1-treated mice was comparable to the percentage found in the animals before challenge (FIG. 6C ). However, a significant CD3+ T cell depletion was observed in theinfected control animals 5 days post-viral challenge (FIG. 6C ) as reported before (Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009). In contrast, the T cell population remained constant before and after challenge in the protected BPZE1-immunized animals (FIG. 6C ), suggesting that BPZE1-treatment prevented influenza-induced lymphocyte depletion. - Major pro-inflammatory cytokines and chemokines were measured in the BALFs recovered from protected BPZE1-treated mice and compared to non-protected mice, 1 and 3 days after lethal H3N2 virus challenge. All the pro-inflammatory cytokines and chemokines measured in the BALFs of the protected animal group were significantly lower than those measured in the non-protected mice (
FIG. 7 ). The differences were observed at bothday 1 andday 3 for IL-1β, IL-6, IFN-γ and TNF-α, which are the main pro-inflammatory cytokines contributing to influenza-induced immunopathology and correlating with disease severity (de Jong M D, et al., “Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia”, Nat Med 12: 1203-1207, 2006; Beigel J H, et al., “Avian influenza A (H5N1) infection in humans: N Engl J Med 353: 1374-1385, 2005; Peiris J S, et al., “Re-emergence of fatal human influenza A subtype H5N1 disease”, Lancet 363: 617-619, 2004; Schmitz N, et al., “Interleukin-1 is responsible for acute lung immunopatholoy but increases survival of respiratory influenza virus infection”, J Virol 79: 6441-6448, 2005). The levels of IFN-α, MCP-1 and RANTES were found significantly reduced 1 day post-viral challenge whereas the production of IL-12(p70), GM-CSF and KC was lower atday 3 post-challenge. Strikingly, complete suppression of IL-12 production was found in the protected animal group, consistent with lower levels of IFN-γ. - Furthermore, no significant difference was detected in the levels of anti-inflammatory cytokines IL-10 and TGF-β between protected and non-protected animals, ruling out the involvement of
type 1 regulatory T cells (Tr1) in the cross-protection mechanisms (FIG. 7 ). - The presence of cross-reactive (and protective) antibodies and/or T cells in the BPZE1-treated animals was examined Firstly, a BLAST search failed to identify any matching epitopes between B. pertussis and influenza A H3N2 and H1N1 viruses (data not shown). Secondly, the immune serum from BPZE1-treated mice did not react with whole H3N2 viral particles in an ELISA assay, neither did it neutralize the virus in an in vitro neutralization assay (data not shown). Thirdly, a high-titer anti-BPZE1 immune serum did not confer any protection against H3N2 lethal challenge in an in vivo passive transfer experiment whereas an immune serum raised against heat-inactivated H3N2 virus gave a 100% protection rate (
FIG. 8A ). Fourthly, proliferation and IFN-γ ELISPOT assays showed that splenocytes from BPZE1-treated mice did not proliferate and did not produce IFN-γ respectively upon stimulation with H3N2 viral particles (FIGS. 8B & C). Altogether, these data strongly support that B. pertussis-specific immunity does not play any role in the cross-protection against influenza A viruses. - Severe respiratory disease and immunopathology together with a high case-fatality rate have become a hallmark of highly pathogenic avian influenza virus infection in humans as well as in other mammalian species. However, the underlying mechanisms accounting for the severe immunopathological effects have yet to be fully elucidated. In particular, relationship between viral load, immunopathology and disease outcome remains elusive. Several previous studies have reported a reduced mortality rate and immunopathology without significant reduction of the viral burden in animal models of influenza infection; For example, reduced inflammatory cell infiltration and pulmonary damage but with delayed viral clearance was observed in mice with disrupted MIP-1α gene (Cook D N, et al., “Requirement of MIP-1 alpha for an inflammatory response to viral infection”, Science 269: 1583-1585, 1995). Likewise, CCR2 (primary receptor for MCP-1)-deficient mice displayed reduced mortality but a significantly elevated viral burden associated with decreased pulmonary cell infiltration and tissue damage (Dawson T C, et al., “Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus”, Am J Pathol 156: 1951-1959, 2000). In contrast, IL-1R knock-out mice showed increased mortality associated with delayed viral clearance but less severe pathology (Schmitz N, et al., “Interleukin-1 is responsible for acute lung immunopatholoy but increases survival of respiratory influenza virus infection”, J Virol 79: 6441-6448, 2005).
- Here, we report that B. pertussis-mediated cross-protection against influenza A viruses does not result a in lower virus load in the lungs. Instead, protected BPZE1-treated mice displayed minimal lung immunopathology and reduced production of the major pro-inflammatory cytokines and chemokines. Our finding is in agreement with the general consensus that disease severity correlates strongly with high cytokines/chemokines levels (La Gruta N L, et al., “A question of self-preservation immunopathology in influenza virus infection”, Immunol Cell Biol 85: 85-92 2007). Cytokine storm, characterized by excessive levels of chemokines and cytokines in the serum and lungs due to uncontrolled activation of the host's immune system, was indeed correlated with the fatal outcome of experimental animals infected with reconstructed 1918 H1N1 and H5N1 influenza viruses (Kash J C, et al., “Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus”, Nature 443: 578-581, 2006; Simon A K, et al., “Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes”, Proc Natl Acad Sci USA 98: 5158-5163, 2001; Kobasa D, et al., “Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus”, Nature 445: 319-323, 2007; Tumpey T M, et al., “Characterization of the reconstructed 1918 Spanish influenza pandemic virus”, Science 310: 77-80, 2005) as well as in humans (de Jong M D, et al., “Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia”, Nat Med 12: 1203-1207, 2006; Beigel J H, et al., “Avian influenza A (H5N1) infection in humans: N Engl J Med 353: 1374-1385, 2005; Uiprasertkul M, et al., “Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans”, Emerg Infect Dis 13: 708-712, 2007; Peiris J S, et al., “Re-emergence of fatal human influenza A subtype H5N1 disease”, Lancet 363: 617-619, 2004). Furthermore, histological and pathological indicators strongly suggest a key role for an excessive host response in mediating at least some of the extreme pathology associated with highly pathogenic influenza viruses. However, the role of each individual cytokine during influenza infection has remained unclear with often both positive and negative effects; Although their production can be important for viral clearance through the recruitment and/or activation of immune effector cells on the site of infection, their inflammatory properties can also lead to tissue damage (La Gruta N L, et al., “A question of self-preservation immunopathology in influenza virus infection”, Immunol Cell Biol 85: 85-92 2007).
- The reduced production of pro-inflammatory cytokines and chemokines in the respiratory tract of the protected BPZE1-treated animals likely impacted on cellular infiltration and immune cell activation; A significantly lower neutrophil counts was indeed observed in the BALFs of the protected animals consistent with lower levels of KC and TNF-α, both cytokines being involved in the recruitment and activation of neutrophils in the infected tissues (La Gruta N L, et al., “A question of self-preservation: immunopathology in influenza virus infection”, Immunol Cell Biol 85: 85-92 2007; Kips J C, et al., “Tumor necrosis factor causes bronchial hyperresponsiveness in rats”, Am Rev Respir Dis 145: 332-336, 1992; Headley A S, et al., “Infections and the inflammatory response in acute respiratory distress syndrome”, Chest 111: 1306-1321, 1997). Furthermore, the suppressed production of IL-12 measured in the protected animals likely impaired the activation of some immune cells such as natural killer (NK) cells and cytotoxic CD8+ T cells. Both cell types have been described potentially harmful and involved in immunopathology upon release of inflammatory mediators (La Gruta N L, et al., “A question of self-preservation: immunopathology in influenza virus infection”, Immunol Cell Biol 85: 85-92 2007). Consistently, IFN-γ production, a hallmark for NK and CD8+ T cell activation, was found significantly lower in the BALFs recovered from the protected animals. In addition, the lower IFN-γ production can affect the neutrophil responses to the virus, including oxidative burst, induction of antigen presentation and chemokine production (Ellis T N and Beaman B L, “Interferon-gamma activation of polymorphonuclear neutrophil function”, Immunology 112: 2-11, 2004; Farrar M A and Schreiber R D, “The molecular cell biology of interferon-gamma and its receptor”, Annu Rev Immunol 11: 571, 1993).
- Interestingly, a significantly higher number of macrophages were observed in the BALFs of protected BPZE1-treated mice despite lower levels of MCP-1 and GM-CSF, involved in monocytes recruitment and differentiation into macrophages, respectively. However, note should be taken that alveolar macrophages (AM) and not tissue resident macrophages constitute the main macrophage population recovered in the BALFs (Jakubzick C, et al., “Modulation of dendritic cells trafficking to and from the airways”, J Immunol 176: 3578-3584, 2006). It is thus conceivable that the protected mice can display a reduced macrophage population in their lung tissues compared to infected control mice.
- AM have been shown to display suppressive effects on the inflammation reaction by regulating T-cell function (Strickland D H, et al., “Regulation of T-cell function in lung tissue by pulmonary alveolar macrophages”, Immunology 80: 266-272, 1993), and by suppressing dendritic cells maturation (Holt P G, et al., “Down-regulation of the antigen presenting function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages”, J Exp Med 177: 397-407, 1993; Bilyk N and Holt P G, “Inhibition of the immunosuppressive activity of resident pulmonary alveolar macrophages by granulocyte/macrophage colony stimulating factor”, J Exp Med 177: 1773-1777, 1993; Stumbles P A, et al., “Airway dendritic cells: co-ordinators of immunological homeostasis and immunity in the respiratory tract”, APMIS 111: 741-755, 2003) and migration to the mesenteric lymph nodes (Jakubzick C, et al., “Modulation of dendritic cells trafficking to and from the airways”, J Immunol 176: 3578-3584, 2006). One can thus hypothesize that the higher number of alveolar macrophages induced upon influenza challenge contributed to the suppression/control of the inflammation in the protected BPZE1-treated animals.
- Furthermore, we found that the CD3+ T cell population remained unchanged in the protected BPZE1-treated animals upon viral challenge whereas a significant reduction in the proportion of CD3+ T cells was found in the infected control mice. Lymphocyte depletion during highly pathogenic influenza infection has been previously reported (Kash J C, et al., “Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus”, Nature 443: 578-581, 2006; Uiprasertkul M, et al., “Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans”, Emerg Infect Dis 13: 708-712, 2007; Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009; Lu X, et al., “A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans”, J Virol 73: 5903-5911, 1999) and experimental evidences have suggested apoptosis as a potential mechanism (Uiprasertkul M, et al., “Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans”, Emerg Infect Dis 13: 708-712, 2007; Lu X, et al., “A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans”, J Virol 73: 5903-5911, 1999). Since no difference in the viral load was observed between protected and non-protected animals, lymphocyte apoptosis can thus not be a direct cytolytic effect of the virus itself. Instead, our data are consistent with previous studies which suggested that in H5N1-infected humans and mice, lymphocyte apoptosis was likely caused by cytokine dysregulation and overactivation of the host immune response (Uiprasertkul M, et al., “Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans”, Emerg Infect Dis 13: 708-712, 2007; Maines T R, et al., “Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response”, Immunol Rev 225: 68-84, 2008). In particular, TNF-α and related TNF-superfamily members including TNF-related apoptosis inducing ligand (TRAIL) are known to induce T cell apoptosis (Simon A K, et al., “Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes”, Proc Natl Acad Sci USA 98: 5158-5163, 2001; Wang J, et al., “The critical role of LIGHT, a TNF family member, in T cell development”, J Immunol 167: 5099-5105, 2001). Consistently, lower levels of TNF-α were measured in the BALFs of protected BPZE1-treated mice upon influenza challenge, thus potentially translating into lower T cell apoptosis.
- The protective mechanisms responsible for the cross-protection have yet to be identified. However, our data demonstrate that B. pertussis-specific adaptive immunity (including cross-reactive antibodies and T cells) is not involved. The observation that live but not dead BPZE1 bacteria confer protection, indicate that bacterial lung colonization, i.e. a prolonged exposure to the host immune system, is necessary to induce the protective mechanism(s). Moreover, induction of the protective mechanisms necessitates more than 3 weeks to develop as mice treated once with live BPZE1 bacteria and challenged 3 weeks later with influenza H3N2 virus were not significantly protected. However, a second BPZE1 treatment allowed to shorten the time necessary to induce the protective mechanisms and enhance the protection rate, suggesting that some memory cells have been produced upon priming that are capable of responding faster and to a greater extent upon a second encounter with BPZE1 bacteria. Finally, it was observed that three consecutive nasal administrations of live BPZE1 bacteria were necessary to confer 50% protection against human A/PR/8/34 (H1N1) influenza virus. The differential protection rates achieved upon H3N2 and H1N1 virus challenge suggest that the molecular disease-mechanisms induced by both viruses are different. However, even though the protection efficiency can vary between subtypes, B. pertussis remains a promising universal vaccine against influenza A viruses.
- Much of the activity of B. pertussis virulence factors is dedicated to immunomodulation so as to suppress, subvert and evade the host defense system (Carbonetti N H, “Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease”, Curr Opin Pharmacol 7: 1-7, 2007). The immune response to B. pertussis is initiated and controlled through toll-like receptor (TLR)-4 signaling, inducing the anti-inflammatory cytokine IL-10 production by dendritic cells (DCs) which could inhibit inflammatory responses and limit pathology in the airways (Higgins S C, et al., “Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology”, J Immunol 171: 3119-3127, 2003). Filamentous hemagglutinin (FHA), the major adhesin produced in B. pertussis, was shown to stimulate IL-10 production and inhibit TLR-induced IL-12 production by macrophages and DCs, resulting in the development of IL-10 secreting type 1 T-regulatory (Tr1) cells (McGuirk P, et al., “Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates
interleukin 10 production by dendritic cells: a novel strategy for evasion of protectiveT helper type 1 responses by Bordetella pertussis”, J Exp Med 195: 221-231, 2002). Interestingly, the systemic administration of FHA was recently found to reduce intestinal inflammation in a T-cell mediated model of colitis, supporting the anti-inflammatory role of FHA (Braat H, et al., “Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule”, Gut 56: 351-357, 2007). However, here no difference in the production of IL-10 and TGF-□ was found between protected and non-protected mice, ruling out a potential involvement of FHA-mediated induction of Tr1 in the cross-protection against influenza A viruses conferred by B. pertussis. - We report here that in a Balb/c mouse model of severe pneumonitis, prior nasal administration of an attenuated strain of Bordetella pertussis (BPZE1), the etiologic agent of whooping cough, provided effective and sustained protection against lethal challenge with a mouse-adapted H3N2 influenza A virus and to a lesser extent against human H1N1 (A/PR/8/34) influenza A virus. Although the cellular and molecular players involved in this cross-protection have yet to be identified, our data indicate that B. pertussis-specific adaptive immunity and Tr1-mediated down-regulation are likely not involved. Importantly, we found that the cross-protection does not result in viral load reduction. Instead, protected BPZE1-treated mice displayed minimal lung immunopathology, consistent with reduced neutrophil infiltration and lower production of a variety of major pro-inflammatory cytokines and chemokines in their BALFs. Our findings thus strongly suggest that protection against influenza A viruses induced-lethal pneumonitis can be achieved through attenuation of inflammation and dampening of the cytokine storm, and demonstrate the potential use of BPZE1 bacteria as an effective prophylactic means of protecting against virulent influenza A virus infections.
- All publications and patent applications cited in this specification are herein incorporated by reference in their entirety for all purposes as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference for all purposes.
- Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.
-
- 1. Carrat F and Flahault A, “Influenza vaccine: the challenge of antigenic drift”, Vaccine 25: 6852-6862, 2007.
- 2. Nicholson K G, et al., “Influenza”, Lancet 362: 1733-1745, 2003.
- 3. Kash J C, et al., “Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus”, Nature 443: 578-581, 2006.
- 4. Simon A K, et al., “Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes”, Proc Natl Acad Sci USA 98: 5158-5163, 2001.
- 5. Kobasa D, et al., “Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus”, Nature 445: 319-323, 2007.
- 6. Tumpey T M, et al., “Characterization of the reconstructed 1918 Spanish influenza pandemic virus”, Science 310: 77-80, 2005.
- 7. de Jong M D, et al., “Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia”, Nat Med 12: 1203-1207, 2006.
- 8. Beigel J H, et al., “Avian influenza A (H5N1) infection in humans: N Engl J Med 353: 1374-1385, 2005.
- 9. Uiprasertkul M, et al., “Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans”, Emerg Infect Dis 13: 708-712, 2007.
- 10. Peiris J S, et al., “Re-emergence of fatal human influenza A subtype H5N1 disease”, Lancet 363: 617-619, 2004.
- 11. Salomon R, et al., “Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection”, Proc Natl Acad Sci USA 104: 12479-12481, 2007.
- 12. de Jong M D, et al., “Oseltamivir resistance during treatment of influenza A (H5N1) infection”, N Engl J Med 353: 2667-2672, 2005.
- 13. Cook D N, et al., “Requirement of MIP-1 alpha for an inflammatory response to viral infection”, Science 269: 1583-1585, 1995.
- 14. Dawson T C, et al., “Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus”, Am J Pathol 156: 1951-1959, 2000.
- 15. Smith D J, et al., “Mapping the antigenic and genetic evolution of influenza virus”, Science 305: 371-376, 2004.
- 16. Renauld-Mongenie G, et al., “Induction of mucosal immune response against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis”, Proc Natl Acad Sci USA 93: 7944-7949, 1996.
- 17. Mielcarek, N, et al., “Nasal vaccination using live bacterial vectors”, Adv Drug Deliv Rev 51: 55-70, 2001.
- 18. Mielcarek N, et al., “Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen”, Infect immune 65: 544-550, 1997.
- 19. Coppens I, et al., “Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis”, Infect immune 69:5440-5446, 2001.
- 20. Reveneau N, et al., “Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis”, Vaccine 20: 926-933, 2002.
- 21. Alonso S, et al., “Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis using filamentous haemagglutinin as carrier”, Infect immune 73: 4295-4301, 2005.
- 22. Mielcarek N, et al., “Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough”, PLoS Pathog 2: e65, 2006.
- 23. Ho S Y, et al., “The highly attenuated Bordetella pertussis BPZE1 strain as a potential live vehicle for the delivery of heterologous vaccine candidates”, Infect Immune 76: 111-119, 2008.
- 24. Narasaraju T, et al., “Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis”, Microbes Infect 11: 2-11, 2009.
- 25. Lu X, et al., “A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans”, J Virol 73: 5903-5911, 1999.
- 26. Schmitz N, et al., “Interleukin-1 is responsible for acute lung immunopatholoy but increases survival of respiratory influenza virus infection”, J Virol 79: 6441-6448, 2005.
- 27. La Gruta N L, et al., “A question of self-preservation immunopathology in influenza virus infection”, Immunol Cell Biol 85: 85-92 2007.
- 28. Kips J C, et al., “Tumor necrosis factor causes bronchial hyperresponsiveness in rats”, Am Rev Respir Dis 145: 332-336, 1992.
- 29. Headley A S, et al., “Infections and the inflammatory response in acute respiratory distress syndrome”, Chest 111: 1306-1321, 1997.
- 30. Ellis T N and Beaman B L, “Interferon-gamma activation of polymorphonuclear neutrophil function”, Immunology 112: 2-11, 2004.
- 31. Farrar M A and Schreiber R D, “The molecular cell biology of interferon-gamma and its receptor”, Annu Rev Immunol 11: 571, 1993.
- 32. Jakubzick C, et al., “Modulation of dendritic cells trafficking to and from the airways”, J Immunol 176: 3578-3584, 2006.
- 33. Strickland D H, et al., “Regulation of T-cell function in lung tissue by pulmonary alveolar macrophages”, Immunology 80: 266-272, 1993.
- 34. Holt P G, et al., “Down-regulation of the antigen presenting function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages”, J Exp Med 177: 397-407, 1993.
- 35. Bilyk N and Holt P G, “Inhibition of the immunosuppressive activity of resident pulmonary alveolar macrophages by granulocyte/macrophage colony stimulating factor”, J Exp Med 177: 1773-1777, 1993.
- 36. Stumbles P A, et al., “Airway dendritic cells: co-ordinators of immunological homeostasis and immunity in the respiratory tract”, APMIS 111: 741-755, 2003.
- 37. Maines T R, et al., “Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response”, Immunol Rev 225: 68-84, 2008.
- 38. Wang J, et al., “The critical role of LIGHT, a TNF family member, in T cell development”, J Immunol 167: 5099-5105, 2001.
- 39. Carbonetti N H, “Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease”, Curr Opin Pharmacol 7: 1-7, 2007.
- 40. Higgins S C, et al., “Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology”, J Immunol 171: 3119-3127, 2003.
- 41. McGuirk P, et al., “Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates
interleukin 10 production by dendritic cells: a novel strategy for evasion of protectiveT helper type 1 responses by Bordetella pertussis”, J Exp Med 195: 221-231, 2002. - 42. Braat H, et al., “Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule”, Gut 56: 351-357, 2007.
- 43. Menozzi F D, et al., “Identification and purification of transferring- and lactoferrin-binding proteins of Bordetella pertussis and Bordetella bronchiseptica”, Infect. Immun 59: 3982-3988, 1991.
- 44. WHO, “WHO Manual on Animals Influenza Diagnosis and Surveillance” (World Health Organization, Geneva), 2002.
- 45. Kimman T G, et al., “Development and antigen specificity of the lymphoproliferation response of pigs to pseudorabies virus: dichotomy between secondary B- and T-cell responses”, Immunology 86: 372-378, 1995.
- 46. Bao Z, et al., “Glycogen synthase kinase-3beta inhibition attenuates asthma in mice”, Am J Respir Crit Care Med 176: 431-438, 2007.
Claims (8)
1. A method of reducing lung immunopathology in a mammalian subject infected with an influenza type A virus, the method comprising the step of: prior to the subject becoming infected with the influenza type A virus, administering to the subject a sufficient amount of a live attenuated, mutated Bordetella pertussis strain to elicit an immune response which reduces influenza type A-induced lung immunopathology in the subject, wherein the live attenuated Bordetella pertussis strain comprises a mutated pertussis toxin (ptx) gene.
2. The method of claim 1 , wherein the immune response elicited is sufficient to confer at least a 50% level of protection.
3. The method of claim 1 , wherein the strain is administered intranasally.
4. The method of claim 1 , wherein at least a first dose and a second dose of the strain are administered to the subject.
5. The method of claim 4 , wherein the second dose is administered to the subject one to three weeks from the administration of the first dose.
6. The method of claim 1 , wherein the live attenuated Bordetella pertussis strain comprises a heterologous ampG gene.
7. The method of claim 1 , wherein the live attenuated Bordetella pertussis strain comprises a deleted or mutated dermonecrotic (dnt) gene.
8. The method of claim 6 , wherein the live attenuated Bordetella pertussis strain comprises a deleted or mutated dermonecrotic (dnt) gene.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/303,512 US20230364217A1 (en) | 2009-06-15 | 2023-04-19 | Influenza vaccine, composition, and methods of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2009/007153 WO2010146414A1 (en) | 2009-06-15 | 2009-06-15 | Influenza vaccine, composition, and methods of use |
US201213377070A | 2012-02-02 | 2012-02-02 | |
US15/353,758 US20170106074A1 (en) | 2009-06-15 | 2016-11-17 | Influenza Vaccine, Composition, and Methods of Use |
US18/303,512 US20230364217A1 (en) | 2009-06-15 | 2023-04-19 | Influenza vaccine, composition, and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/353,758 Continuation US20170106074A1 (en) | 2009-06-15 | 2016-11-17 | Influenza Vaccine, Composition, and Methods of Use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230364217A1 true US20230364217A1 (en) | 2023-11-16 |
Family
ID=43355934
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/377,070 Active US9526778B2 (en) | 2009-06-15 | 2009-06-15 | Influenza vaccine, composition, and methods of use |
US15/353,758 Abandoned US20170106074A1 (en) | 2009-06-15 | 2016-11-17 | Influenza Vaccine, Composition, and Methods of Use |
US18/303,512 Pending US20230364217A1 (en) | 2009-06-15 | 2023-04-19 | Influenza vaccine, composition, and methods of use |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/377,070 Active US9526778B2 (en) | 2009-06-15 | 2009-06-15 | Influenza vaccine, composition, and methods of use |
US15/353,758 Abandoned US20170106074A1 (en) | 2009-06-15 | 2016-11-17 | Influenza Vaccine, Composition, and Methods of Use |
Country Status (8)
Country | Link |
---|---|
US (3) | US9526778B2 (en) |
EP (2) | EP2442826B1 (en) |
JP (1) | JP5551774B2 (en) |
CN (1) | CN102802665B (en) |
CA (1) | CA2765364C (en) |
DK (1) | DK2442826T3 (en) |
SG (1) | SG176532A1 (en) |
WO (1) | WO2010146414A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007224734C1 (en) | 2006-03-10 | 2016-07-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Live attenuated Bordetella strains as a single dose vaccine against whooping cough |
EP2442826B1 (en) * | 2009-06-15 | 2015-07-08 | National University of Singapore | Influenza vaccine, composition, and methods of use |
WO2013066272A1 (en) * | 2011-11-02 | 2013-05-10 | National University Of Singapore | Effect of an attenuated bordetella strain against allergic disease |
EP2722338A1 (en) | 2012-10-17 | 2014-04-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel recombinant Bordetella strains |
WO2016001907A1 (en) * | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
US9655959B2 (en) | 2014-10-01 | 2017-05-23 | National University Of Singapore | Adenylate cyclase deficient bordetella strains |
CN114767718A (en) | 2016-03-29 | 2022-07-22 | 里尔巴斯德研究所 | Mutant bordetella strains and methods of use thereof |
SG11202003333WA (en) | 2017-10-18 | 2020-05-28 | Pasteur Institut | Bordetella strains expressing serotype 3 fimbriae |
TWI657824B (en) * | 2017-12-29 | 2019-05-01 | 財團法人生物技術開發中心 | A universal vaccine against influenza |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
WO2024018061A1 (en) * | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Use of bordetella strains for the treatment of chronic obstructive pulmonary disease |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8205892D0 (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US6713072B1 (en) | 1987-11-02 | 2004-03-30 | Chiron S.R.L. | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
ATE188613T1 (en) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | VACCINE COMPOSITION CONTAINING ADJUVANTS |
HU219056B (en) | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
FR2718750B1 (en) | 1994-04-19 | 1996-06-14 | Pasteur Institut | Recombinant proteins of the filamentous hemagglutinin of Bordetella, in particular, B. Pertussis, production and application to the production of foreign proteins or vaccinating active principles. |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
FR2754543B1 (en) | 1996-10-11 | 1998-12-31 | Pasteur Institut | BORDETELLA STRAIN DEFICIENT IN TOXIN PRODUCTION AND EXPRESSING HYDRID PROTEIN, LIPOSOMES COMPRISING FHA AND THEIR USES AS VACCINES, AND THE USE OF FHA TO STIMULATE IMMUNE RESPONSES |
DK1005368T3 (en) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
DE69838992T2 (en) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Oil-in-water emulsions with saponins |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
AU756828B2 (en) | 1997-12-02 | 2003-01-23 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
PL354714A1 (en) | 1998-04-09 | 2004-02-09 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE69935606T9 (en) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | ADJUVANCE SYSTEMS AND VACCINE |
JP2003509452A (en) | 1999-09-24 | 2003-03-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | Adjuvant containing polyoxyethylene alkyl ether or ester and at least one nonionic surfactant |
EP1221971A2 (en) | 1999-09-24 | 2002-07-17 | SmithKline Beecham Biologics SA | Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
EP1311288A1 (en) | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
ES2298269T3 (en) | 2000-09-26 | 2008-05-16 | Idera Pharmaceuticals, Inc. | MODULATION OF THE IMMUNO-STIMULATING ACTIVITY OF OLIGONUCLEOTIDIC ANALOGS IMMUNO-STIMULANTS THROUGH POSITIONAL CHEMICAL CHANGES. |
ATE398461T1 (en) | 2001-02-13 | 2008-07-15 | Us Gov Sec Army | VACCINES FOR TRANSCUTANEOUS IMMUNIZATION AGAINST TRAVEL DIARRHEA |
JP2004529906A (en) | 2001-03-19 | 2004-09-30 | イオマイ コーポレイシヨン | Percutaneous immunostimulation |
GB0123580D0 (en) | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
FR2840319B1 (en) | 2002-05-30 | 2004-08-20 | Pasteur Institut | BORDETELLA STRAINS MADE DEFICIENT BY GENETIC ATTENUATION |
AU2004229527B2 (en) | 2003-04-11 | 2009-08-20 | Medimmune, Llc | Methods of preventing or treating respiratory conditions |
AU2007224734C1 (en) | 2006-03-10 | 2016-07-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Live attenuated Bordetella strains as a single dose vaccine against whooping cough |
JP2010508860A (en) * | 2006-11-15 | 2010-03-25 | フォリア バイオテック インコーポレイテッド | Influenza vaccine based on papaya mosaic virus |
EP2170921A4 (en) * | 2007-06-18 | 2012-08-08 | Hemispherx Biopharma Inc | Early intervention of viral infections with immune activators |
AU2010243708C1 (en) | 2009-04-28 | 2014-10-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vaccine for prophylaxis or treatment of an allergen-driven airway pathology |
EP2442826B1 (en) * | 2009-06-15 | 2015-07-08 | National University of Singapore | Influenza vaccine, composition, and methods of use |
-
2009
- 2009-06-15 EP EP09846104.9A patent/EP2442826B1/en active Active
- 2009-06-15 EP EP15172430.9A patent/EP2944320A1/en not_active Withdrawn
- 2009-06-15 DK DK09846104.9T patent/DK2442826T3/en active
- 2009-06-15 JP JP2012515573A patent/JP5551774B2/en active Active
- 2009-06-15 WO PCT/IB2009/007153 patent/WO2010146414A1/en active Application Filing
- 2009-06-15 CA CA2765364A patent/CA2765364C/en active Active
- 2009-06-15 SG SG2011088697A patent/SG176532A1/en unknown
- 2009-06-15 US US13/377,070 patent/US9526778B2/en active Active
- 2009-06-15 CN CN200980160953.1A patent/CN102802665B/en active Active
-
2016
- 2016-11-17 US US15/353,758 patent/US20170106074A1/en not_active Abandoned
-
2023
- 2023-04-19 US US18/303,512 patent/US20230364217A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2442826A1 (en) | 2012-04-25 |
EP2944320A1 (en) | 2015-11-18 |
CN102802665A (en) | 2012-11-28 |
WO2010146414A1 (en) | 2010-12-23 |
EP2442826B1 (en) | 2015-07-08 |
JP2012530128A (en) | 2012-11-29 |
CA2765364C (en) | 2015-05-26 |
SG176532A1 (en) | 2012-01-30 |
US20170106074A1 (en) | 2017-04-20 |
US9526778B2 (en) | 2016-12-27 |
CA2765364A1 (en) | 2010-12-23 |
JP5551774B2 (en) | 2014-07-16 |
EP2442826A4 (en) | 2012-12-12 |
US20120121647A1 (en) | 2012-05-17 |
DK2442826T3 (en) | 2015-09-21 |
CN102802665B (en) | 2015-11-25 |
AU2009348207A1 (en) | 2012-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230364217A1 (en) | Influenza vaccine, composition, and methods of use | |
AU2012331646B2 (en) | Effect of an attenuated Bordetella strain against allergic disease | |
CN115190911B (en) | Composition having immunogenicity against SARS coronavirus 2, its preparation method and use | |
US9950059B2 (en) | Immunogenic composition | |
WO2022037248A1 (en) | Live attenuated sars-cov-2 virus immunogenic compositions, methods of making and using | |
US20230089695A1 (en) | Compositions immunogenic against sars coronavirus 2, methods of making, and using thereof | |
AU2009348207B2 (en) | Influenza vaccine, composition, and methods of use | |
JP5995329B2 (en) | Influenza vaccines, compositions, and methods of use | |
WO2020097923A1 (en) | Live attenuated influenza b virus compositions methods of making and using thereof | |
JP2016172779A (en) | Influenza vaccine, composition, and methods of use | |
US20240050558A1 (en) | Compositions immunogenic against influenza and sars coronavirus 2, methods of making and using thereof | |
CN116635068A (en) | Compositions having immunogenicity against influenza and SARS coronavirus 2, methods of making and using the same | |
CN105412919A (en) | Influenza vaccine, composition and use method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |